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Abstract 
 
Background 
 
The HOPE trial showed that ramipril reduced cardiovascular morbidity and 
mortality in patients with peripheral arterial disease (PAD). However, 
evidence regarding the effect of angiotensin converting enzyme (ACE) 
inhibitors on walking distance, ankle brachial pressure index (ABPI), arterial 
stiffness and quality of life (QoL) in this group of patients is limited. 
 
Objective 
The aim of this study is to investigate ACE inhibitors effect on clinical 
parameters of PAD, arterial stiffness and QoL in patients with intermittent 
claudication (IC).  
  
Methods   
33 patients (25 males, mean age: 65+/-7.8) with IC (Fontaine stage II or 
higher) were randomised to receive ramipril (5 mg once daily for 2 weeks 
increased to 10 mg once daily for 22 weeks, n=14) or placebo (n=19) for 24 
weeks in a double-blind study. Walking distance was assessed using a 
standard laboratory treadmill test (2.5 km/hr at 10% incline). ABPI was 
assessed pre (r-ABPI) and post-exercise (t-ABPI). Arterial stiffness indices 
were measured using the SphygmoCor device. 
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Results 
After 24 weeks, ramipril improved maximum treadmill walking distance; 
adjusted mean change difference (95% confidence interval); by 130.5 (61.8 to 
199.2) m longer than placebo (P=0.001), improved treadmill intermittent 
claudication distance by 121.9 (55.9 to 187.8) m longer than placebo 
(P=0.001) and improved patient reported walking distance by 159 (5.5 to 
313) m compared to placebo (P=0.040). Ramipril reduced carotid femoral 
pulse wave velocity (a measure of arterial stiffness) by -1.47 (-2.4 to -0.57) 
m/s compared to placebo (P=0.002). However, r-ABPI and t-ABPI minimally 
changed in both groups (Ramipril 0.02 (-0.08 to 0.11) vs. placebo 0.03 (-0.05 
to 0.10, P=0.830) and (Ramipril 0.04 (-0.04 to 0.12) vs. placebo 0.02 (-0.04 to 
0.09), P=0.720), respectively. Ramipril had a slight insignificant effect on QoL 
physical domains compared to placebo.  
 
 
Conclusion 
Ramipril improves walking distance in patients with IC; however, this 
improvement is not related to improvement in ABPI but might be due to 
ramipril ability to reduce arterial stiffness. ACE inhibitors effect on QoL needs 
to be validated in a larger randomised controlled trial.     
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…“Show me a thoroughly satisfied 
man and I will show you failure.                 
I believe that restlessness is 
discontent and discontent is merely 
the first necessity of progress” 
 
Thomas Alva Addison 
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1.1.2. Mechanism of action: 
1.1.3. Effects of ACE i 
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1.1. Lower Limb Peripheral Arterial Disease and 
Intermittent Claudication 
 
 
Opening Statement 
 
Peripheral arterial disease (PAD) of the lower limbs is a common disorder and 
an important marker of cardiovascular risk. It is associated with mortality 3-5 
times that of an age-matched population mainly due to cardiovascular and 
cerebrovascular events such as myocardial infarction (MI) and stroke. PAD 
can be classified into: asymptomatic and symptomatic or intermittent 
claudication (IC). Asymptomatic PAD is usually suspected during clinical 
examination of the lower limbs pedal pulses. It can be diagnosed by 
measuring the Ankle Brachial Pressure Index (APBI). APBI measurement is a 
simple and usually confirms the presence of the disease. It is calculated by 
dividing the ankle pressure by the highest measured systolic brachial blood 
pressure (bBP). An ABPI of ≤ 0.9 is usually diagnostic of PAD of the lower 
limbs. IC, which is the focus of this thesis, is a clinical diagnosis given to 
muscle ache or pain classically in the calf during a period of exercise and is 
relieved after a short period of rest.  
 
Epidemiology  
The annual incidence of IC is difficult to measure; however, the prevalence of 
the disease is more important and ranges from 3% in patients aged 40 to 6% 
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in patients aged 60 1. Based on several large population studies which looked 
at prevalence of IC, the disease is more prevalent in men in the younger age 
groups but occurs equally in men and women at older ages.  
 
Aetiology 
IC can be defined as exercise-induced pain or fatigue that affects a group of 
muscles in the lower limb which is relieved after a short period of rest.  Other 
features of IC include:  Progression over time, the pain increases and 
becomes severer while doing the same usual functions due to disease 
progression, the anatomical correlations of some risk factors for PAD with 
some segments of the arterial tree, for instance, diabetes mellitus (DM) with 
infrapopliteal arteries and smoking and hypertension with aortoiliac arteries 
and the level of stenosis or arterial involvement is usually above the area of 
pain. However, classical symptoms of claudication are not always featured 
leading to a 90% of cases with PAD of the lower limbs being missed 1-3.         
 
Risk Factors   
 
Several risk factors have been associated with an increased risk of developing 
PAD leading to IC. These risk factors include non-modifiable risk factors such 
as race, gender and age and modifiable risk factors such as DM, 
hypertension, smoking and hypercholesterolaemia.  
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Non-modifiable Risk Factors   
I. Race: The GENOA (Genetic Epidemiology Network of Arteriopathy) 
study 4 showed differences in the prevalence of PAD among different 
ethnic groups and that this difference is independent of the difference 
in classical risk factors for atherosclerosis among these groups. 
Furthermore, the National Health and Nutrition Examination Survey 
(NHANES) in the United States 5 showed that the percentage of non-
Hispanics Blacks who had an ABPI ≤ 0.9 was more than Whites (7.8% 
versus 4.4%, respectively). 
II. Gender: The prevalence of PAD of the lower limbs is more common in 
men especially in the younger age groups; however, the prevalence 
decreases and becomes similar in both men and women in the older 
age groups. In patients with IC, the ratio of men to women is between 
1:1 and 2:1 and sometimes reaches 3:1 in more advanced stages of the 
disease.   
III. Age: Newman 6 found that an ABPI which is diagnostic of PAD is evident 
in 12% of adults above the age of 50. Of those about a third suffers 
from IC.   
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Modifiable Risk Factors 
i. DM: Diabetes is one of the strongest risk factors associated with PAD. IC 
is twice as common in patients with DM as in non-diabetic patients. 
There is an increased risk of PAD of about 26% with every 1% increase 
in HbA1c in patients with DM 7.  PAD in patients with DM is more 
aggressive than in non-diabetic patients with early involvement of large 
arteries and distal symmetrical neuropathy. In a cross-sectional study of 
4153 Greek adults 8, the odds ratio (OR) for vascular disease was 1.94 
(95 per cent confidence interval (95% CI) 1.35 to 2.47) in patients with 
metabolic syndrome and 3.04 (1.98 to 4.11) in patients with metabolic 
syndrome and DM. Thus, the risk of PAD increased with a combination 
of metabolic syndrome and DM. Moreover, the need for amputation is 
five to ten times higher in patients with DM than in non-diabetics. This 
could be attributed to neuropathy and increased infection rate in 
diabetic patients.  
ii. Hypertension: The National Health and Nutrition Examination Survey 5 
showed an association between hypertension and PAD. In brief, some 
2174 patients more than 40 years old were included in the survey. The 
prevalence of PAD was 4.3%. In patients above the age of 70 years the 
prevalence was 14%. There was a strong association between 
hypertension and PAD among other risk factors assessed in this survey 
(OR 1.75, 95% CI 0.97 to 3.13).  
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iii. Smoking: Smoking is another important risk factor for PAD. It promotes 
endothelial dysfunction and affects lipid metabolism and coagulation 9. 
The Edinburgh artery study 10 involved 1592 men and women aged 57-
74 years old randomly selected from several general practices across 
Scotland showed that smoking is strongly associated with PAD and that 
the association was stronger than with coronary artery disease (CAD). 
Cigarette smoking also increased biomarkers of coagulation and 
endothelial function. The OR of PAD increased 7.3 times (95% CI 4.2 to 
12.8) by smoking 25 cigarettes of more.  
iv.  Hypercholesterolaemia: High cholesterol concentration and familial 
hyperlipidaemia are significant risk factors for atherosclerosis and PAD. 
The prevalence of PAD increases by 5 folds to 10 folds in patients with 
familial hypercholesterolaemia. Treatment with statins, therefore, has 
the potential to decrease the risk of PAD and increasing the walking 
distance in patients with IC. Ridker et al.11 compared the predictive 
value of 11 lipid and non-lipid biomarkers as risk factors for PAD in 
14916 healthy U.S male physicians aged 40 to 84 years. Multivariable 
analysis showed that the total cholesterol-high density lipoprotein 
cholesterol (HDL-C) ratio (Relative risk (RR) for those in the highest 
versus lowest quartile, 3.9; 95% CI 1.7 to 8.6) and C - reactive protein 
(CRP) (RR for the highest versus lowest quartile, 2.8; 95% CI 1.3 to 5.9) 
were the strongest independent predictors for development of PAD. 
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Arterial Wall Structure and the Extracellular Matrix 
The structure of arteries and veins is generally similar with the walls 
comprising three concentric layers. The tunica adventitia is the strong 
outermost layer of both veins and arteries. It comprises connective tissue, 
collagen and elastin as well as nerves which supply the vessel and its nutrient 
vessels. 
The tunica media is the middle, thickest layer and contains a circular 
arrangement of elastin, connective tissue and particularly in arteries vascular 
smooth muscle, which is responsible for the calibre of the vessel. 
The tunica intima is the thinnest layer and in arteries this layer is composed 
of an internal elastic membrane lining and a single layer of smooth 
endothelial cells. The difference between veins and arteries is that veins do 
not contain the elastic membrane lining and in some veins the tunica intima 
is folded back on itself to form valves (Figure 1). 
  
 
Figure 1: Arterial wall structure. Adapted from Jacob 2003
12 
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The extracellular matrix (ECM) plays a vital role in the structure of the arterial 
wall. The cells of the three layers of the arterial wall are embedded within 
their ECM. Endothelial cells lie on the basement membrane of the intima. 
This basement membrane consists of collagen type IV. Collagen and Elastin 
are the most important components of the arterial wall and they regulate the 
arterial wall function and the biomechanical properties of the arterial wall are 
influenced by the quantities of these two constituents. 
The arterial wall is a dynamic organ composed of endothelium, medial 
smooth muscle and fibroblast cells invested in ECM (Figure 1). Vascular 
smooth muscle cells not only control wall tension but also synthesize the 
major structural components of the vessel wall 13.  
The ECM consists of the scaffolding elements of collagen and elastin 
embedded in glycoproteins and proteoglycans (Table 1). Therefore, the 
stability, resilience and compliance of the vascular wall are dependent on the 
contribution of these imminent components. The relative content of these 
molecules is normally held stable by a slow but dynamic process of 
degradation and production. Dysregulation of this balance, mainly by 
stimulation of an inflammatory milieu, leads to overproduction of abnormal 
collagen and diminished quantities of normal elastin, resulting in an increase 
in arterial stiffness.  
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Structural Component Molecules Main Properties 
Collagen fibres Type I and III collagens (90%) 
Types V, VI, VIII, XII, XIV, XV and 
XVIII collagens 
Tensile strength 
Elastic fibres Elastin (90%) 
Fibrillin-1 and -2,  
MAGP-1 et -2,  
Emilin-1 et -2,  
Fibulin-5 
Elasticity 
Basement membrane of 
endothelial cells and smooth 
muscle cells 
Type IV collagen 
Laminin, Entacten 
Perlecan (HS-PG) 
Filtration and resistance 
 
 
 
 
 
Other components 
Proteoglycans: 
Versican (CS-PG), hyaluronan 
Biglycan (DS-PG), decorin (DS-
PG), lumican (KS-PG) (Small PG) 
 Syndecans (HS-PG), glypican (HS-
PG) (Cell-associated PG) 
Hydration, filtration,  
interaction with other 
ECM components, 
reservoir of growth 
factors 
Structural glycoproteins: 
Fibronectins, Vitronectin 
Interactions between 
ECM molecules via 
integrins 
Matricellular proteins:  
Thrombospondins, 
Tenascins, Osteopontin 
Structure, bioreactivity 
 
 Table 1: Structural components and main properties of the extracellular matrix. ECM:  
Extracellular matrix, MAGP: Microfibrillar – associated glycoproteins, HS-PG: Heparan 
sulphate proteoglycan, CS-PG: Chondroitin sulphate proteoglycan, DS-PG: Dermatan 
sulphate proteoglycan, KS-PG: Keratan sulphate proteoglycan. Adapted from Jacob 200312 
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Angiotensin II stimulates both myocardial and vascular collagen expression 14 
and inhibition of the renin-angiotensin system (RAS) will reduce the collagen 
deposition 15,16 and increase the elastin/collagen ratio leading to a reduction 
in arterial stiffness 16-21.  
The regulation of the changes in ECM structure is partly mediated by matrix 
metalloproteinases (MMPs) which not only play a role as extracellular 
degrading enzymes but also exert effects on cellular growth and 
proliferation11. MMPs include collagenases (MMP-1, expressed by 
endothelial cells and MMP-8), gelatinases (MMP-2, expressed by vascular 
cells, MMP-9, expressed in macrophages and inducible in vascular cells), 
elastases (MMP-7, expressed by the vascular wall, MMP-12, synthesized 
during the differentiation of monocytes into macrophages), stromelysins and 
membrane-type matrix metalloproteinases (MT-MMPs). The proteolytic 
activity of each MMP is regulated at three levels. Firstly, gene expression and 
protein secretion levels, secondly, activation of the inactive pro-enzyme and 
thirdly, inhibition of tissue inhibitors of MMPs (TIMPs) or other inhibitors 
such as α2- macroglobulin.  
Collagen and elastin are potently regulated by the catabolic MMPs which 
degrade the ECM by creating uncoiled less effective collagen and broken and 
frayed elastin molecules 22-24 increasing the stiffening of the arterial wall. 
(Arterial stiffness will be discussed in more detail in c chapter 3).  
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Clinical Features of IC 
Symptoms and signs   
The majority of patients with PAD have limited exercise performance and 
walking ability which can have a huge effect on their quality of life. The 
classical symptom in patients with PAD of the lower limbs is IC. This means 
that these patients limb due to the pain they experience while walking. This 
exercise-induced pain is caused by ischemia and is relieved after a short 
period of rest. The pain is most commonly localised to the calf but can affect 
the thigh and buttocks depending on the artery affected by atherosclerosis. It 
is worth mentioning that patients without classical symptoms of IC can also 
have walking limitations and experience atypical or no limb symptoms 25. 
Patients also might not experience typical claudication symptoms due to 
them having conditions such as congestive heart failure, pulmonary disease 
or musculoskeletal disease which will prevent them from exercise and 
producing the symptoms of claudication. PAD is caused by atherosclerosis 
which causes stenosis and/or occlusion of the major arteries that supply the 
lower limbs. Patients with IC have no limbs symptoms at rest because they 
will have a normal and sufficient blood flow to the lower limbs. However, 
during exercise, the increased blood flow to the lower limbs is limited by the 
occlusive lesions in the arteries causing a mismatch between oxygen supply 
and the muscles metabolic demand which will produce the symptoms of 
claudication.    
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Clinical signs that are found in a patient with IC include, but are not limited 
to, changes in skin colour and temperature of the lower limbs, muscle 
atrophy due to lack of exercise, decreased hair growth and slow-growing and 
hypertrophied nails. Bruits could be auscultated over the major arteries 
supplying the lower extremities and indicate the presence of a turbulent 
blood flow due to stenosis and/or occlusion. The absence of bruits, however, 
does not exclude arterial disease. Examination of the pulses of the lower 
limbs is of paramount importance in the assessment of a patient with IC. A 
diminished or absent femoral pulse would suggest aortoiliac disease which 
suggests diminished blood inflow and a palpable femoral pulse and an absent 
pedal pulse would suggest arterial disease in the lower leg with preserved 
inflow. Moreover, isolated lesions in the internal iliac arteries could be 
associated with normal femoral and pedal pulses at rest but associated with 
buttock claudication and (impotence in males).  Similarly, isolated lesions in 
the external iliac arteries produce similar signs of normal femoral and pedal 
pulses in the lower limbs at rest. Nevertheless, these pulses will not be 
maintained during exercise due to peripheral occlusive lesions limiting blood 
flow to the lower limbs.  
 
Diagnosis  
Figure 3 illustrates an algorithm for the diagnosis of PAD.  
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Ankle Brachial Pressure Index  
Measurement of ABPI has become a standard part of the initial evaluation of 
a patient with PAD of the lower limbs. The method of measurement is simple 
and involves using a 10–12 cm sphygmomanometer cuff placed just above 
the ankle and a Doppler instrument used to measure the systolic pressure of 
the posterior tibial and dorsalis pedis arteries of each leg. The resulting ankle 
pressure values from each leg are then divided by the highest systolic bBP of 
either arm. The index leg is the leg with the lower ABPI.  The ABPI provides 
important information in the assessment of a patient with symptomatic PAD 
(IC). A reduced ABPI confirms the presence of an occlusive disease between 
the heart and the ankle of the affected leg. An ABPI ≤0.9 is usually diagnostic 
of PAD and the lower the ABPI, the more severe the occlusion would be. ABPI 
also aids in the differential diagnosis of patients presenting with pain of the 
lower limbs induced by exercise; a normal ABPI will rule out the presence of 
arterial occlusive disease and other causes of exercise-induced pain in the 
lower limbs should be sought. Additionally, ABPI provides valuable prognostic 
information about the risk of developing cardiovascular events which is 
independent of other standard risk factors. For instance, an ABPI ≤ 0.9 is 
associated with a three to six fold increased risk of cardiovascular mortality. 
Therefore, ABPI has the potential to provide additional prognostic 
information when combined with other cardiovascular risk predictors such as 
the Framingham risk score (FRS).  
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Treadmill exercise test  
Treadmill exercise testing is used mainly in patients with normal ABPI at rest 
such as patients with iliac artery disease where exercise can induce a 
decrease in ABPI which is measured immediately after walking on a treadmill 
and once detected confirms the diagnosis of PAD. These patients will walk on 
a treadmill at a typical speed of 3.2 km/h at an incline of 10%-12% until 
claudication pain occurs or for a maximum of 5 minutes1.  A decrease in ABPI 
of 10%-15% is normally diagnostic of PAD.  
 
Colour-assisted Duplex Ultrasonography 
Duplex ultrasonography provides an attractive alternative to angiography. It 
is non-invasive, less expensive and in the correct hands can provide most of 
the anatomical information needed. Moreover, it can provide additional 
information such as velocity gradients across stenosis. The whole arterial tree 
can be visualized and assessed for the presence of occlusive lesions. 
However, crural arteries are challenging and cannot be visualised easily. 
Other limitations include the long time the test needs and the need for 
experience and training.  
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Figure 2: Algorithm for the diagnosis of PAD. TBI: toe brachial index, VWF: velocity wave 
form, PVR: pulse volume recording. This algorithm has been adapted from Hiatt et al.26  
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Angiography 
Angiography is considered the gold standard test but has some risks. These 
include severe reaction to the contrast material which can cause renal failure 
in patients with deranged renal function, bleeding, infection, 
pseudoaneurysm, haematoma, atherothrombotic events and carries a risk of 
mortality of about 0.17% 1. Nevertheless, despite all the previously 
mentioned complications, digital subtraction angiography of the arterial tree 
from the renal to the pedal arteries remains the investigation of choice in 
patients with PAD.  
Magnetic Resonance Angiography  
Magnetic resonance angiography (MRA) is rapidly becoming the preferred 
diagnostic and treatment planning technique in patients with PAD. It 
produces a 3D image of the arterial tree which can be rotated and studied in 
detail enabling pre-procedural treatment planning. To this end, it has been 
widely used in the planning for endovascular procedures.  
Disadvantages of MRA include the exclusion of some patients with metal 
implants due to the high magnetic field, claustrophobia and the artifacts 
produced by some stents in the peripheral arteries which makes assessment 
of these segments difficult. However, calcified arteries such as in patients 
with DM or renal failure can be visualised on MRA in contrast to other 
imaging techniques.  
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Biomarkers Associated with PAD 
PAD is associated with increased cardiovascular morbidity and mortality. 
There have been several biomarkers associated with PAD, however, a few are 
used in routine clinical practice. The most important biomarkers associated 
with PAD are C-reactive protein (CRP), N-terminal pro B natriuretic peptide 
(NTproBNP), Fibrinogen  and urine albumin creatinie ratio which is an 
indicator of urine albumin excretion rate.  
Patients with PAD have several vascular beds affected by the disease such as; 
coronary, cerebral and renal ones. This may account for the increased 
mortality and morbidity associated with PAD due to cardiovascular and 
cerebrovascular events. It is essential to stratify and treat  cardiovascular risk 
factors early to prolong survival in this patients’ cohort. Biomarkers, 
therefore, can serve as indicators of the disease helping clinicians to identify 
patients with PAD at increased risk of cardiovascular, cerebrovascular or 
renovascular events. 
  
C - reactive protein 
 
CRP which is a marker of low- grade inflammation is mainly produced in the 
liver in response to pro-inflammatory cytokines such as IL-627 and is widely 
used in evaluating patients suffering from various inflammatory disorders. 
There is a link between the severity of PAD and the inflammation caused by 
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atherosclerosis where a number of pro-inflammatory cytokines such as: IL-6 
and tumor necrosis factor-α are produced 28 causing an increase in serum CRP 
levels. There also seems to be an inverse relationship between ABPI and CRP 
levels29. Burke et al.30 have also shown that CRP is a marker of vascular 
inflammation and that the higher the CRP levels the higher the number of 
vascular beds affected by atherosclerosis. Moreover, high serum CRP levels 
have shown to be associated with increased risk of cardiovascular events in 
patients with PAD31,32. Beckman et al31 demonstrated that CRP and ABPI 
independently or in combination predicted acute coronary syndrome, stroke 
or death in patients with PAD. Furthermore, The Pravastatin or Atorvastatin 
Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 
study33 showed that lowering CRP with statin therapy improves 
cardiovascular outcomes independent of the reduction in serum cholesterol 
levels. Serum CRP levels adds prognostic information to clinicians that might 
guide clinical work-up and therapy intensity. In our trial we hypothesized ,as 
reported in several previous observational studies34-37 that Ramipril reduces 
CRP serum levels in patients with PAD, therefore, reducing inflammation 
associated with PAD which leads to a reduction in cardiovascular morbidity 
and mortality.  
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Fibrinogen 
The components of the clotting cascade can be hypothesized to be useful 
predictors of atherosclerosis and subsequent complications. Ridker et al. 38 
have shown that elevated fibrinogen levels are a consistent risk factor for 
atherothrombosis. Smoking, DM, hypertension, hypercholesterolaemia and 
inflammation are all causes for elevated fibrinogen levels. In patients with 
PAD, elevated fibrinogen levels are associated with increased cardiovascular 
events39. Measurement of fibrinogen in patients with PAD allows for 
identifying patients with increased risk of cardiovascular events who could be 
targeted with fibrate lowering medications which has a lipid and fibrate 
lowering effect40. In this trial, we hypothesized that ramipril reduces 
fibrinogen levels resulting in a reduction in cardiovascular events in patients 
with PAD.  
 
Urine Albumin Creatinine Ratio 
Shearman et al.41 and Hickey et al.42 have reported that urinary microalbumin 
concentrations increase following exercise in patients with intermittent 
claudication. The reason behind this is that severe ischaemia produced by 
exercise can initiate an acute inflammatory response which causes 
endothelial cell damage and a systemic increase in vascular permeability. 
Microalbuminuria results from an increase in the glomerular filtration of 
albumin and probably reflects a generalised increase in vascular permeability 
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to macromolecules. Additionally, Matsushita et al.43 showed in a cohort study 
of 15 patients with IC that the post-exercise urinary microalbumin elevation 
was related to the MWD. For patients with an elevated urinary microalbumin 
concentration, microalbuminuria can be used as a marker for IC and help to 
evaluate the effects of treatments. It can also be a predictor of cardiovascular 
prognosis and a manifestation of widespread atherosclerosis. In this trial we 
hypothesized that ramipril reduces microalbuminuria in patients with PAD 
resulting in decreased cardiovascular events and a reduction in 
atherosclerosis.    
 
N-terminal pro B-type natriuretic peptide 
The amino-terminal fragment of B-type natriuretic peptide prohormone 
(NTproBNP) is a marker of cardiac function and is increased in symptomatic 
and asymptomatic heart disease44,45.  NTproBNP has been shown to be a 
robust and independent predictor of all-cause mortality in patients with PAD 
and is considered a valuable tool for risk stratification in this patients’ 
cohort46. Although NTproBNP is a surrogate marker of left ventricular systolic 
dysfunction and is increased in patients with heart failure, some studies have 
shown that NTproBNP plasma levels are increased in patients with 
atherosclerosis irrespective of left ventricular function45,47. Therefore, finding 
potential causes that may contribute to increased NTproBNP levels in 
patients with atherosclerosis and understanding the mechanism behind this 
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increase could be essential to decrease the associated high cardiovascular 
morbidity and mortality.  
NTproBNP serum levels were measured in this trial to assess the impact of 
ramipril on cardiac function. The rationale behind this is that ramipril by 
reducing serum levels of NTproBNP would result in improved cardiac function 
and prognosis.  
 
The Fate of the Leg   
The overall prognosis for a patient with PAD is poor with a cumulative annual 
mortality of about 5%. In patients with IC, however, the prognosis for the 
limb is more benign with 75% of patients’ symptoms remaining stable/ 
improving with only a small minority progressing to critical limb ischaemia. 
This stabilization of symptoms may be due to the development of collaterals, 
metabolic adaptation of ischaemic muscle or the alteration of gate in favour 
of the non-ischaemic muscle groups.  
In addition, major amputations are a rare outcome of IC. A large scale study48 
found that the rate of amputation in unselected patients with PAD was less 
than 2% (Figure 4) 49.        
 
Treatment   
The treatment options for IC can be classified into non-invasive 
(Conservative) and invasive.   
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Non-invasive (Conservative) Management  
Supervised Exercise Programme              
Supervised exercise programmes (SEP) have a well-established role in the 
treatment of patients with IC with significant clinical and quality of life (QoL) 
improvements 50,51.    
Two Cochrane reviews have shown that SEP is as effective as percutaneous 
transluminal angioplasty (PTA) in the treatment of stable claudicants 52,53. SEP 
works by a combination of factors including optimised structural and 
metabolic performance of skeletal muscle, improvement in rheological 
parameters, development of collaterals, improved walking technique and 
marked psychological benefit 54.  In prospective studies, involving SEP, which 
have been conducted for 3 months or longer, there have been significant 
increases in treadmill walking distances and a reduction in claudication pain 
during exercise 55.    
 
Pharmacotherapy  
 
The focus of the pharmacotherapy is to reduce the symptoms of claudication 
and decrease the risk of cardiovascular morbidity and mortality associated 
with PAD.  
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Cilostazol  
Cilostazol is a vasodilator drug with antiplatelet properties, and was approved 
for treatment of intermittent claudication in 1999 26. A meta-analysis of eight 
randomised control trials 56 (RCTs) and a more recent Cochrane review 57 
concluded that cilostazol demonstrated significant improvement in walking 
distances and QoL for these patients as compared to placebo. Dawson et al.58 
investigated the effect cilostazol and pentoxifylline in 698 patients. 
Treatment with pentoxifylline improved walking distance to a similar extent 
as placebo. However, cilostazol improved walking distance by 54% from 
baseline. Cilostazol is a selective type III phosphodiesterase inhibitor, thereby 
increasing the intracellular concentration of cyclic adenosine 
monophosphate. This results in vasodilatation improving blood flow through 
the peripheral arteries. Additionally, it inhibits platelet aggregation, 
thrombus formation and vascular smooth muscle proliferation 26,56.  
 
Lipid Lowering Drugs 
Statins have shown to improve walking distance and decrease cardiovascular 
morbidity and mortality in PAD patients. Aronow et al.59 found that 
simvastatin significantly increased treadmill claudication time by 24% at 6 
months and 42% at 1 year compared to placebo. Mondillo et al.60 reported 
similar improvement after short term therapy with simvastatin in 43 patients 
with IC and elevated cholesterol. Treadmill walking distance significantly 
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improved after simvastatin therapy by 126 metres and this was the case for 
ABPI which improved by 0.09.  
 
Antithrombotic Agents (Aspirin or ADP-receptor Antagonists Clopidogrel or 
Ticlopidine)   
Antithrombotic agents play an essential role in reducing the increased risk of 
cardiovascular events associated with PAD61. However, they have shown no 
benefit in improving the symptoms associated with PAD62.   
 
Vasodilators  
This group of therapeutic agents were the first to be used for treatment of IC. 
Examples of these drugs include: α-blockers, direct vasodilators, β2 agonists, 
calcium channel blockers (CCBs) and  ACE inhibitors. This group of drugs, 
apart from ACE inhibitors showed no benefit in improving claudication 
symptoms. The clinical effectiveness of ACE inhibitors in patients with IC is 
the main focus of this thesis. Summary of studies with their conclusions 
which assessed the effect of ACE inhibitors in IC is provided in chapter 2.     
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Figure 3: The fate of the claudicant over 5 years. CLI: critical limb ischaemia; CV: cardiovascular; MI: myocardial infarction. Adapted from Hirsch et al.49
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Invasive Management 
Percutaneous Transluminal Angioplasty   
PTA is the first line invasive treatment for patients with IC with significant 
clinical and QOL improvements63,64. However, long term results for PTA are 
highly variable depending upon the level of lesion; with better outcomes for 
aortoiliac disease as compared to infrainguinal disease65.  More recent trials 
have demonstrated that the beneficial effects of PTA can be increased by 
combining it with other treatment modalities for sustained improvement in 
clinical and QoL parameters with reduction in need for re-intervention66,67. 
PTA works by increasing the blood flow to the limb by physically opening the 
narrowing in blood vessel.  
 
1.2 Angiotensin Converting Enzyme Inhibitors    
The rennin angiotensin system (RAS) plays a major role in cardiovascular 
disease, and over the last decade intensive research has investigated the 
possible clinical benefit of ACE inhibitors. They competitively inhibit ACE, a 
non-specific enzyme involved in the metabolism of many small peptides, 
including the conversion of angiotensin I, an inactive octapeptide, into 
angiotensin II, the actions of which are summarised in table 1. 
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Pharmacokinetics 
ACE inhibitors are classified in 3 categories according to the group which 
binds the zinc atom of the ACE molecule into those containing a sulfhydril, a 
carboxyl or a phosphoryl group as the zinc ligand. Absorption is variable 
amongst ACE inhibitors, but peak plasma concentrations are generally 
reached 1-4 hours after ingestion 68. Some ACE inhibitors are pro drugs and 
remain inactive until they are converted into active metabolites by hydrolysis 
in the liver or gastrointestinal system. Most ACE inhibitors & their 
metabolites are excreted via the renal route but some have a balanced 
elimination through the renal and hepatic routes. Captopril has a very short 
elimination half-life, accounting for its short duration of action whereas 
ramiprilat (the active metabolite of ramipril) is eliminated more slowly than 
the other ACE inhibitors. In patients with renal impairment (Creatinine 
clearance <30ml / min) renal excretion is reduced thus dose reductions are 
usually necessary to prevent elevated maximum plasma drug levels and 
toxicity 69-71.  
Mechanism of Action  
RAS has traditionally been regarded as a circulating endocrine system, 
however 90% of ACE is tissue bound. There are important differences in the 
binding affinity to tissue ACE between ACE inhibitors, with some 
demonstrating high affinity (tissue ACE inhibitors e.g. – perindopril, ramipril) 
and others low affinity (plasma ACE inhibitors e.g. captopril, enalapril, 
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lisinopril). It may be hypothesised, with some supporting evidence that the 
clinical effects in excess of that which may have been anticipated by BP 
lowering effects frequently observed in ACE inhibitor trials, are more 
common in trials of tissue than plasma ACE inhibitors72-75.  
ACE inhibitors also inhibit kininase, and increase bradykinin levels which in 
turn stimulates the B2 receptors, leading to the release of nitric oxide and 
vasoactive prostaglandins (prostacyclin & prostaglandin E2)76,77.  
 
ACE Inhibitors Effects  
Haemodynamic Effects   
ACE inhibitors decrease total peripheral vascular resistance and promote 
natriuresis but cause little change in heart rate (HR) – no reflex tachycardia or 
impaired HR during exercise / postural changes are observed. ACE inhibitors 
reduce endothelial dysfunction in patients with coronary artery disease, 
hypertension, non-insulin dependent DM and heart failure via the kininase 
inhibition pathway.  
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Table 2: Effects of Angiotensin II. LHRH: Luteinizing hormone releasing hormone, ACTH: 
Adrenocorticotropin hormone, NO: Nitric oxide, PA:  Plasminogen activator inhibitor, VCAM:  
Vascular cell adhesion molecule, ICAM: Intracellular adhesion molecule, MCP: Monocyte chemo-
attractant protein, IL6: Interleukin 6, MAPK: Mitogen activated protein kinase, PDGF: Platelet derived 
growth factor, IGF: Insulin like growth factor, ECMP: Extracellular matrix proteins, MMP: Matrix 
metalloproteinases, NADH / NADPH: Nicotinamide adenine dinucleotide / nicotinamide adenine 
dinucleotide phosphate 
Vessels 
 
Vasoconstriction 
Stimulates noradrenaline, aldosterone, vasopressin & endothelin 
I release 
Heart 
 
Inotropic and chronotropic effects 
Coronary vasoconstriction 
 
Adrenal gland Aldosterone & adrenaline release 
Brain 
 
Vasopressin, Substance P, LHRH & ACTH release 
Thirst centre stimulation 
Increased sympathetic activation 
Kidney 
 
Vasoconstriction  
Contraction of mesangial cells 
Increased Na reabsorption in proximal tubule 
Increased K excretion in distal nephron 
Decreased rennin release 
Platelets Stimulates adhesion & aggregation 
Endothelial Cells 
 
Inactivation of NO (inhibits endothelial nitric oxide synthase) 
Expression of endothelial oxLDL receptor (LOX-1) 
Sympathetic outflow 
 
Enhancement of peripheral noradrenergic neurotransmission 
Catecholamine release from adrenal medulla 
Fibrinolysis Increased expression of PAI 1 & 2 
Inflammation 
 
Activation & migration of macrophages 
Increased expression of adhesion molecules (VCAM 1, ICAM 1 & P 
selectin) 
Increased expression of chemotactic proteins (MCP 1) & 
cytokines (IL6) 
Trophic effects 
 
Hypertrophy of cardiac myocytes 
Stimulation of vascular smooth muscle migration, proliferation & 
hypertrophy 
Stimulates proto oncogenes and MAPKs 
Increased production of growth factors (PDGF, bFGF, IGF-1) 
Increased synthesis of ECMPs (fibronectin, collagen type I & III) 
and MMPs 
Stimulation of NADH / NADPH oxidase activity, superoxide anion 
production and lipid peroxidation 
 
Atherosclerosis 
 
Stimulation of NADH / NADPH oxidase activity, superoxide anion 
production and lipid peroxidation 
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Renal Effects    
ACE inhibitors decrease renal vascular resistance, increase renal blood flow 
and promote excretion of sodium & water, whilst maintaining glomerular 
filtration rate.  
 
Neurohormonal Effects  
Short-term ACE inhibitor treatment decreases plasma levels of angiotensin II, 
aldosterone, noradrenaline, adrenaline & vasopressin. During chronic ACE 
inhibitor therapy angiotensin and aldosterone levels return to pre-treatment 
values via aldosterone “escape” pathway. 
 
             Side Effects of ACE Inhibitors 
 
a. Hypotension: symptomatic hypotension due to the blockade of 
angiotensin II mediated vasoconstrictor tone is relatively common 
especially following first dose and is dose dependant.  
b. Dry Cough: Appears in 5-10% of patients, is not dose dependant and is 
more common in women and Asian populations. It usually develops 
between 1 week and 2 months of treatment initiation and may 
necessitate treatment withdrawal, following which the cough disappears 
within 3-5 days. It is due to the increase in bradykinin levels and 
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demonstrates no difference in propensity amongst the different ACE 
inhibitors. 
c. Hyperkalaemia: Rare among patients with normal renal function, but 
more frequent in the elderly, patients with heart failure, impaired renal 
function, receiving potassium or potassium sparing diuretics, heparin or 
NSAIDs. 
d. Acute renal failure: Occurs more frequently in patients with volume 
depletion (high diuretic doses), bilateral renal artery stenosis, stenosis of 
the dominant renal artery or a single kidney and renal transplant 
recipients. 
e. Angioedema: A rare but life threatening side effect. Generally occurs 
within the first month of treatment and disappears within hours of ACE 
inhibitor withdrawal.  
f. Teratogenic effect: When ACE inhibitors are administered during the 2nd 
or 3rd trimester of pregnancy.  
g. Other side effects:  Ageusia and other taste disturbances, neutropenia 
(rare) and maculopapular rash. 
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Clinical Indications   
 
I. Heart Failure: There is clear level 1 evidence (based on data from 
multiple RCTs & meta-analyses) that ACE inhibitors are first line 
therapy in patients with chronic heart failure of all degrees of 
severity78-81. 
II. Acute MI – Early Intervention: In high risk patients (Clinical signs of 
heart failure 82 or left ventricular dysfunction 80,81) following acute MI, 
there is clear level 1 evidence that ACE inhibitors reduce mortality. In 
low risk unselected patients following acute MI, clinical trials have 
demonstrated benefit in terms of mortality to be marginal 83-85 or 
negligible86,87. Indeed in the meta-analysis of the ACE Inhibitor in 
Myocardial Infarction Collaborative Group88, including over 100 000 
patients, 30 day mortality was reduced from 7.6% in the placebo 
group to 7.1% in the ACE inhibitor group (Adjusted RR (ARR) 0.5%, 
number needed to treat (NNT) to prevent 1 death = 200). No benefit 
was observed in low risk groups (inferior MI, no heart failure) or 
diabetics and ACE inhibitors were associated with an excess of 
persistent hypotension (17.6% versus 9.3%) and renal dysfunction 
(1.3% versus 0.6%). A consensus document clearly states that this 
small benefit may not be sufficient enough to recommend the use of 
ACE inhibitors in large groups of low risk, unselected patients89.  
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III. Hypertension: A number of large, long term follow up trials compared 
different therapeutic strategies and could not demonstrate an 
unequivocal difference in favour of a particular antihypertensive 
agent90-92. A meta-analysis, including 9 RCTs, comparing old drugs 
(diuretics and β-blockers) against CCBs and ACE inhibitors in 62, 605 
hypertensive patients, found no difference in outcome between the 
different antihypertensives93. It seems that the level of blood pressure 
reduction is more important than the antihypertensive used, 
therefore the selection of a specific antihypertensive must be based 
on individual patient profiles.  
IV. Stroke: ACE inhibitors are superior to placebo in reducing recurrent 
stroke (ARR 4%) but not all cause mortality in patients with a history 
of stroke or transient ischaemic attack over a 4 year follow up 
period94. This may be attributed to the significant fall in blood 
pressure in the ACE inhibitor group as a reduction in stroke as an 
endpoint has not been observed in other RCTs in high risk patients 
comparing different antihypertensive agents91,95.  
V. Chronic Kidney Disease: Interim analysis in a RCT comparing ACE 
inhibitors to CCBs in 1094 African Americans with hypertensive 
nephrosclerosis suggested retarded renal disease progression, but 
evidence for long term benefit was lacking96. 
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VI. DM: In a study (ADVANCE) of 11, 140 type 2 diabetic patients, with a 
history of major cardiovascular disease or at least one other risk 
factor for cardiovascular disease, randomised to perindopril and 
indapamide demonstrated a reduction in major macro or micro 
vascular events after a mean of 4.3 years follow up (ARR 1.3%, P = 
0.040, NNT over 5 years to prevent 1 death = 79)97. Moreover in 13 
101 adults with hypertension and type 2 diabetes enrolled in the 
antihypertensive and lipid lowering treatment to prevent heart attack 
(ALLHAT) trial, diuretics were equivalent to ACE inhibitors in reducing 
cardiovascular complications98. However evidence suggests that in 
type 2 diabetics with hypertension and microalbuminuria, ACE 
inhibitors provide combined cardiovascular and renal protection and 
are therefore recommended99,100. In the diabetic population of the 
HOPE study significant differences in the primary outcome only 
became evident 2 years after treatment initiation101. 
VII. High Risk Cardiovascular Patients with no Left Ventricular 
Dysfunction or Heart Failure: The HOPE study randomised 9297 
patients with high risk of cardiac events (History of CAD, stroke, PAD, 
or DM plus at least one other cardiovascular risk factor – 
hypertension, elevated total cholesterol / Low density lipoprotein 
cholesterol (LDL-C), smoker, microalbuminuria) without evidence of 
heart failure or left ventricular dysfunction to an ACE inhibitor 
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(ramipril) or placebo. Ramipril was associated with a significant 
reduction in the composite primary outcome of MI, stroke or 
cardiovascular death (ARR 3.8% - P < 0.001)102. 
VIII. Low Risk Cardiovascular Patients:  The Prevention of Events with 
Angiotensin Converting Enzyme inhibition (PEACE) trial in 8290 
patients with stable coronary disease randomised to ACE inhibitor or 
placebo demonstrated no significant difference in primary outcome 
(cardiovascular death, MI and coronary revascularisation) after a 
median follow up of 4.8 years (ARR 0.6%, P = 0.430)103. The EUROPA 
trial in 13 655 patients with stable coronary disease without evidence 
of heart failure or substantial hypertension found a small but 
significant benefit in primary end point (cardiovascular death 
myocardial infarction or cardiac arrest) in patients randomised to ACE 
inhibitor (ARR 2%, P = 0.003) over a mean follow up period of 4.2 
years104. 
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Introduction 
Several studies (RCTs) investigated the effect of ACE inhibitors on walking 
ability in patients with PAD of the lower limbs. These studies examined the 
effect of a variety of ACE inhibitors on walking distance and ABPI. However, 
they lacked power and the duration of treatment with ACE inhibitors was 
short. In order to increase the power of these studies we performed a meta-
analysis of published data to investigate the effect of ACE inhibitors on 
maximum walking distance (MWD) or time (MWT) as a primary outcome 
measure and pain-free walking distance (PFWD) or time (PFWT) and ABPI as 
secondary outcome measures in patients with IC105. 
Systematic Review and Meta-analysis 
The literature was searched using MEDLINE, EMBASE and Cochrane Central 
Register of Controlled Trials (CENTRAL) databases on RCTs written in English 
from 1966 to 2010. Studies were eligible to be included in our review if they 
were: 1. RCTs which compared any kind of ACE inhibitors with placebo or no 
treatment 2. Included patients with symptomatic PAD of the lower limbs (IC) 
as either the study population or a subgroup 3. Used MWD and/or PFWD 
and/or ABPI as outcome measures. Minimum period of treatment with ACE 
inhibitors was one month.  
Overall, studies included a total of 576 patients. There were 334 (58%) males 
and 242 (42%) females, with a mean age of 60.7 years, age range (58-66). Of 
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which, 137 (24%) patients had symptomatic PAD of the lower limbs. Patients’ 
characteristics are summarised in table 3 and RCTs which were included in 
the systematic review are summarised in table 4.  
Description of Included Studies  
A double blind, placebo- controlled, crossover trial of antihypertensive 
treatment in 23 patients with hypertension and PAD, failed to demonstrate 
any statistically significant benefit of captopril  25 mg twice daily over 
placebo in terms of PFWD and MWD (149 +/- 71.5 metres vs. 145 +/- 89.4 
metres and 228 +/- 143 metres vs. 226 +/- 151.9 metres, respectively)106 . 
Captopril preserved lower limb arterial circulation possibly by maintaining 
the collateral blood supply which could be attributed to the lack of 
angiotensin II vasoconstriction effect caused by ACE inhibition and reduced 
breakdown of bradykinin.  
Indeed, a placebo controlled, crossover, RCT of ACE inhibition with cilazapril 
(2.5mg/day) for 8 weeks in 23 claudicants demonstrated a deleterious effect 
on treadmill walking time107. Mean MWT was longer in the placebo group 
8.04 +/- 6.39 min (431 +/- 343 meters) than the cilazapril group 6.05 +/- 5.01 
min (325 +/- 269 meters), P < 0.009. ABPI was higher, but statistically 
insignificant, after treatment in the placebo group than the cilazapril group 
(0.69 +/- 0.12 vs. 0.66 +/- 0.15), P > 0.050.  
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A multicentre, double blind, RCT of 54 patients with essential hypertension 
and claudication (Fontaine IIb) randomised to perindopril 4mg once daily (n= 
26) or matching placebo (n=28) for 6 weeks found that there was a slight but 
not a statistically significant increase in PFWD in favour of the perindopril 
group (173 +/- 17 meters vs. 165 +/- 10 meters)108. In terms of MWD, 
patients in the placebo group walked a significantly longer distance than the 
perindopril group (369 +/- 46 meters vs. 323 +/- 43 meters, respectively). This 
difference was found to be statistically insignificant according to the authors. 
There was no difference in the ABPI in both groups after treatment (0.75 +/- 
0.05).  
Finally, a further double blind trial109 randomised 40 intermittent claudicants 
with superficial femoral artery disease to either ramipril 10 mg once daily or 
matched placebo for 24 weeks (20 patients per group) and found ramipril in 
comparison to placebo to be associated with statistically significant 
improvements in PFWT, 381 +/- 124 sec (339 +/- 110 meters) in the ramipril 
group vs. 161 +/- 29 sec (143 +/- 26 meters) in the placebo group, P < 0.001. 
This was also the case for MWT, 687 +/- 181 sec (611 +/- 161 meters) in the 
ramipril group vs. 234 +/- 31.4 sec (208 +/- 28 meters) in the placebo group, P 
< 0.001, ankle brachial pressure indices at rest and post exercise and Walking 
Impairment Questionnaire scores. The changes in ABPI with ramipril (0.73 +/- 
0.09 in the ramipril group vs. 0.50 +/- 0.10 in the placebo group, P < 0.001) 
were found to be due to a reduction in brachial systolic blood pressure at rest 
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and both a reduction in brachial systolic blood pressure and an increase in 
ankle pressure post exercise. Ahimastos et al.109 used a strict inclusion criteria 
which limited the applicability of the results to non-diabetic patients with 
infrainguinal arterial disease. 
 
Results of Systematic Review 
ACE Inhibitors Effect on MWD   
Maximum walking distances/times were pooled successfully from all four 
studies106-109. After analysing these data, we found significant heterogeneity 
among the groups and no significant difference in the pooled treatment 
effect (standard mean difference = 0.46, 95 per cent CI (-0.99 to 1.92), P = 
0.530, I²=95%) (Figure 5).  
ACE Inhibitors Effect on PFWD 
Pain free walking distance/time could be pooled from three studies106,108,109. 
Analysis of these data showed significant heterogeneity and no significant 
differences in the pooled treatment effect (standard mean difference 0.97, 
95 per cent C.I. (-0.24 to 2.18), P=0.120, I2= 90%) (Figure 6).  
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ACE inhibitors effect on ABPI  
Ankle Brachial Pressure Indices were also pooled from three studies107-109 and 
analysis of data showed significant heterogeneity and no significant 
differences in the pooled treatment effect (Standard mean difference 0.68, 
95 per cent C.I. (-0.70 to 2.06), P=0.330, I2=93%) (Figure 7).  
 
Discussion of Systematic Review 
This systematic review and meta-analysis has highlighted the contradicting 
evidence regarding the impact of ACE inhibition on treadmill walking 
distances in patients with IC; as 3 out of 4 studies reported negative results; 
however, these studies were not properly powered and two of them were 
crossover trials106,107. Crossover trials are not likely to be suitable for 
evaluating disease progression and severity because treatment effects are 
not fully reversible after each treatment. Moreover, the variation in findings 
may reflect variability in patient subgroups, disease distribution, and 
dose/duration of treatment. Long term (>24 weeks) treatment of non-
diabetic patients with isolated infrainguinal disease would seem to infer 
maximal benefit. 
Further data from RCTs is required to analyse the effectiveness of ACE 
inhibitors for symptom relief, generic and disease specific QoL and perhaps 
the vascular endothelium in patients with IC.  
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Figure 4: Forest plot illustrating ACE inhibitors effect on MWD. CI: confidence interval, SD: standard deviation, IV: inverse variance 
 
 
 
Figure 5: Forest plot illustrating ACE inhibitors effect on PFWD. For further explanation see legend for figure 5  
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Figure 6: Forest plot illustrating ACE inhibitors effect on ABPI. For further explanation see legend for figure 5 
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First Author Year Age, y Male 
n (%) 
Baseline ABPI Diabetes Mellitus 
n(%) 
BMI 
Kg/m2 
Current 
Smokers 
n(%) 
SBP 
mmHg 
DBP 
mmHg 
Roberts106 1987 58 17(74) <0.9 0(0) NR 9(39) NR 115 
Spence107 1993 60 16(70) 0.69 NR NR NR 138 83 
Overlack108 1994 59 263(54) 0.68 106(22) 27 NR 160 100 
Ahimastos109 2006 66 38(95) 0.56 0(0) 24 17(43) 139 85 
 
Table 3: Characteristics of patients included in the systematic review. ABPI: Ankle brachial pressure index, BMI: Body mass index, SBP: Systolic blood pressure, DBP: 
Diastolic blood pressure, NR: Not reported
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First Author Year Type Jaddad 
Score 
Total No. of 
patients 
Type of 
ACEI 
 
Dose Follow 
up 
Outcome 
Roberts106  1987 RCT 4/5 23 Captopril 50mg/day 6 
months 
No effect on pain free and maximum walking 
distances  
Spence107  1993 RCT 4/5 23 Cilazapril 2.5mg/day 8 weeks No effect on leg blood flow & adverse effect on 
walking time on a treadmill 
Overlack108  1994 RCT 4/5 490     
 (54 with clinical 
PAD) 
Perindopril 4mg/day 6 weeks No effect on pain free and maximum walking 
distances 
Ahimastos109  2006 RCT 5/5 40 Ramipril 10mg/day 24 
weeks 
Improved pain free and maximum walking distances  
 
Table 4: Summary of RCTs which assessed ACE inhibitors effect on walking distance and/or ABPI. RCT: Randomised controlled trial, PAD: Peripheral arterial disease
Arterial Stiffness                                                    Chapter 3 
 
66 
 
History  
The history of the clinical importance of arterial stiffness goes back to as early 
as the 200 BC in the ‘Yellow Emperor’s Classic of Internal Medicine’. Chinese 
physicians identified the association of pulse change with disease; however, 
their method of assessment of the pulse did not go beyond manual 
palpation110.  
In 1880, the English psychologist C.S.Roy described that elastic vessels which 
are found mainly in children are more desirable than stiff ones111 which was a 
remarkable finding given the era. In 1863, more significant advances in the 
area of arterial stiffness were made by Etienne Marey, a French 
chronophotographer, by developing the Sphygmograph112 (Figure 7). This 
device was made of brass, ivory, steel and wool. The arterial pulse waveform 
was recorded using a steel spine tipped with ivory which was applied over 
the radial artery. He then studied the correlation between pulse wave 
progression, cardiac cycle and heart sounds 113.     
Fredrick Akbar Mahomed established the foundation of pulse wave analysis 
(PWA) in 1872. He studied the radial artery waveform and illustrated a 
difference between it and the carotid waveform. He also studied the effect of 
hypertension on the radial artery waveform 114.  Sir William Broadbent (1890) 
and Mackenzie (1902) went on to develop the device further and thus began 
the era of sphygmocardiography.  
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Figure 7: Etienne Marey Sphygmograph (Taken from Nelson et al112) 
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Definition  
Arterial stiffness describes the rigidity of the artery. It can be defined as the 
resistance of an elastic body to deflection by an applied force 115.  It is one of 
the earliest detectable manifestations of structural and functional changes 
within the vessel wall. Arterial stiffness is associated with several pathological 
conditions116-119 and has been identified as an independent risk factor for 
cardiovascular disease120. 
  
Understanding Arterial Stiffness 
To better understand arterial stiffness, there are some key concepts that 
need to be highlighted: 
1. The Windkessel principle:  Large arteries have the function of being a 
conduit for blood to reach peripheral tissues; however, another 
function is to provide adequate buffering for each ventricular systole 
through arterial-ventricular coupling. Therefore, the aorta varies in its 
histology dependent on the function of its sections. For instance, 
proximal aorta is more elastic which allows it to act as a reservoir for 
blood produced after each stroke volume and the distal aorta is stiffer 
as it is more collagenous allowing it to mainly act as a conductive 
system to peripheral tissues121.  
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2. Stress, Laplace’s law and strain: Stress (σ) can be defined as the force 
applied to an area of an object (F/A). Laplace’s law determines the 
circumferential stress in a blood vessel which is directly proportional 
to the vessel pressure and its radius and inversely proportional to the 
vessel thickness. On the other hand, strain (ϵ) can be defined as the 
percentage change in the length of an object which has been 
subjected to stress. It can be calculated as: 
ϵ=L-L0/L0 
where L0 is the initial length and L is the final length.  
3. Young’s elastic modulus (E): This is defined as the ratio between 
stress and strain. The relationship between stress and strain is 
nonlinear in most studies where the slope determines the intrinsic 
elastic properties of the vessel wall. Young’s elastic modulus can be 
calculated as:  
E=σ/C 
where C is the vessel compliance.  
4. Arterial compliance (C): Compliance is defined as the change in a 
vessel diameter (∆D) at a given pressure (∆P) at a fixed vessel length. 
It is the reciprocal of stiffness and can be calculated as:  
C=∆D/∆P 
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5. Distensibility: Defined as relative change in compliance and it is the 
inverse of the elastic modulus.  
6.  Stiffness: Defined as the resistance to deformation. Stiffness 
measurement depends on three variables of any studied vessel (E, h 
and r) according to the Moens-Korteweg equation which calculates 
pulse wave velocity (PWV) considering there are no significant 
changes in vessel wall thickness as: 
PWV=√ (Einc.h)/ (2rp) 
where Einc is the incremental elastic modulus, h is the vessel wall 
thickness, r is the vessel radius and p is the density of the blood. From 
the equation we note that PWV is proportional to the square root of 
the stiffness of the vessel and that it is not sensitive to changes in the 
vessel wall thickness or dimensions. This formula illustrates that the 
most important determinant of stiffness in a blood vessel is the 
percentage of elastin to collagen within its wall, hence the more 
elastic the blood vessel is the lesser the stiffness.  
 
How to Measure Arterial Stiffness?  
There are several methods to assess arterial stiffness in clinical and research 
settings. These include measurement of arterial compliance and distensibility 
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by ultrasound, cardiac MRI and the oscillometric or applanation tonometry 
method.  Arterial stiffness can be quantified using PWV and PWA.  The 
applantation tonometry technique will be explained in further detail in the 
methods section (Chapter 5).  
 
Pulse Wave Velocity 
The gold standard method of quantifying arterial stiffness is PWV and more 
specifically the carotid-femoral PWV (PWVcf) or otherwise called aortic PWV. 
This is due to its simplicity, accuracy and reproducibility 122-124. Other 
suggested methods of measurement include the brachial-ankle PWV or 
brachial-radial PWV, which to date, have shown no predictive value in terms 
of cardiovascular risk.  
PWV is an indirect measure of arterial stiffness which is based on estimating 
the velocity of the pressure wave travelling between two arterial sites. The 
velocity is related to the stiffness of the arterial segment between the two 
measurement sites such that increased arterial stiffness is associated with 
increased PWV.  It is calculated as the distance travelled between the two 
arterial sites divided by the time required for the pulse waveform to travel 
between these two sites: 
PWV (metres/second) =Distance (metres)/tt (second) 
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where tt is transit time.  
PWV is a regional functional assessment of stiffness over a certain arterial 
length, whereas, strain, compliance and distensibility are local measures of 
elasticity.  It is best described by the Moens-Korteweg equation (Mentioned 
above). A more useful equation is the Bramwell-Hill equation125 which 
describes the relationship between distensibility and PWV and expressed in 
meters/second: 
PWV=√1/Dp 
where D is distensibility and p is blood density.  
 
Pulse Wave Analysis  
Pulse can be described as a series of harmonics travelling the arterial tree 
which can be described in terms of dimension, flow and pressure. These 
pulse waveforms transmit energy rather than matter along the arterial tree. 
Therefore, and as the arterial tree is a closed circuit, when the pulse 
waveform reaches a point of resistance such as a bifurcation in the arterial 
tree or an atheroma, this will generate a waveform which is reflected back to 
the origin (the heart) during diastole. Thus, the pulse waveform is formed 
from two components: the incident wave which is generated by the left 
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ventricle and the reflected or returned wave. The summation of both waves 
will form the arterial pulse waveform (Figure 9)126.   
 
Figure 8: Arterial waveform divided into forward travelling incident wave and a reflected 
wave 
 
Wave reflection is an integral part of the arterial pulse waveform. This is 
important in relation to the timing of return of the waveform in relevance to 
the cardiac cycle. For instance, a wave reflected during the cardiac ejection 
systolic period due to increased PWV or reflection from a more proximal 
arterial site or prolonged ejection time will augment systole. Systolic 
augmentation will lead to increased cardiac loading which potentially can 
cause left ventricular hypertrophy, systolic or diastolic cardiac failure or left 
atrial strain and enlargement which will lead to atrial fibrillation with 
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thromboembolic events112. Conversely, a decreased PWV, a more distal wave 
reflection arterial site and a shorter ejection time will result in the reflected 
wave arriving during diastole. Augmentation of diastole will result is 
increased coronary perfusion and decreases left ventricular systolic 
workload.   
Multiple indices can be derived from the pulse waveform (Figure 10) 
including: Augmentation pressure (AP), augmentation index (AIx), aortic 
(central) systolic and diastolic blood pressures, mean arterial pressure (MAP),  
ejection duration (ED) and subendocardial viability ratio (SEVR).  
 
Augmentation Pressure and Augmentation Index 
Wave reflection generates an amount of pressure which augments the aortic 
or central pressure; this is called AP. AIx is the ratio between AP and central 
pulse pressure (PP). AIx is primarily a measure of wave reflections; however, 
due to its correlation with PWV127, it has been considered a measure of 
arterial stiffness too. Therefore, AIx is a composite measure of wave 
reflection and arterial stiffness. Nevertheless, Kelly et al. 128 found that AIx 
correlated with PWV, BP and age in a univariate analysis but only with age in 
multivariate analysis. This suggests that the correlation becomes stronger as 
the aorta ages and becomes stiffer. Therefore, in an elastic aorta, the AIx is 
more likely to be representative of the wave reflection rather than its 
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velocity126. As AIx is influenced by variations in HR129, it has been adjusted to 
75 beats/min which can be calculated by some devices that use the 
applanation method in AIx measurement such as the SphygmoCor device. 
This measurement is called AIx@75.  
AIx is the most important derivative of the arterial pulse waveform with 
several studies indicating its cardiovascular prognostic value130,131.   
 
Subendocardial Viability Ratio or Buckberg Ratio 
The area under the curve (AUC) of the systolic and diastolic portions of the 
central aortic pulse waveform can be measured using PWA132. During diastole 
blood flow occurs in the coronary artery. The diastolic-AUC represents 
myocardial perfusion (Oxygen supply) while the systolic-AUC represents 
myocardial contraction (Oxygen-demand).  SEVR is the ratio between supply 
and demand or diastolic-AUC divided by systolic-AUC. In healthy coronary 
arteries, subendocardial ischaemia occurs at levels below 50%133.  
 
Ejection Duration  
PWA can also be used to calculate the duration of the left ventricular systolic 
ejection duration or the systolic time interval in milliseconds132. The ratio of 
the systolic ejection duration to the total duration of the cardiac cycle is 
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called ED index (ED %). It has been shown that patients with systolic 
dysfunction have higher ED% than patients with diastolic dysfunction132.  
 
Figure 9: Arterial pulse wave with indices derived from PWA. PP: Pulse pressure, AP: 
Augmentation pressure, ED: Ejection duration or time to reflected wave. Adapted from 
Crilly et al134 
 
Factors that Affect Pulse Wave Analysis and Velocity 
Several factors can affect PWA and PWV including:  
I. Age: Arteries become stiffer as they age. This is due to hyperplasia of the 
intima and loss of elastin in the media layer and its replacement with 
collagen. These changes in the arterial wall structure that occur with 
ageing will result in an increase in PWV and AIx135,136. In healthy middle 
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aged adults, the normal values of PWVcf vary according to the arterial 
site. These are 4m/s in the ascending aorta, 5m/s in the carotids and 
abdominal aorta, 7m/s in the brachial artery and 8m/s in the iliac 
arteries137.  On the other hand, AIx normal values range from 5% in 
healthy females less than 20 years old to 37% in females aged from 80 to 
90 years135.  In healthy males, however, AIx values range from -2% in the 
less than 20 years old to 30% in males aged between 80 and 90 years 
old135.  
II. Height: An inverse relationship exists between body height and AIx127,128. 
Yasmin and Brown127 explained this by the shorter distance that the 
reflected wave has to travel back to its origin at a given PWV. This can 
explain the increase of AIx in women compared to men. Nonetheless, this 
inverse relationship between AIx and short stature could be due to the 
increase of cardiovascular risk in patients with decreased height138,139.  
III. HR: It is well known that AIx is influenced by changes in HR. This was 
demonstrated in patients with normal left ventricular function who 
underwent diagnostic cardiac catheterisation140. The right atrium was 
paced to increase the heart rate and this produced a decrease in the AIx 
by 5.6% for each 10 beats/min increase in the heart rate. The relationship 
between PWV and HR, however, is not as clear. While some studies did 
not show a relationship127,141, other studies did142-144.  
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IV. Atherosclerosis and DM:  Several studies have shown that PWV 
correlates with treated and non-treated cardiovascular risk factors of 
atherosclerosis included in the FRS145,146.  PWV also correlated with 
insulin, cholesterol and triglycerides in other studies147,148. Carotid intima 
thickness is a recognised marker of atherosclerosis, not only in the carotid 
artery, but also a reflection of atherosclerosis in the coronary arteries149, 
have also shown a positive correlation with PWV150. Therefore, increased 
atherosclerosis risk will increase PWV and arterial stiffness.  
PWV is also increased in patients with DM type 2. McVeigh et al have 
shown that arterial stiffness, assessed invasively in the brachial artery, 
was increased in a population of patients with DM type 2 before 
cardiovascular manifestations of DM were apparent151. Furthermore, 
arterial stiffness was increased in healthy offspring of patients with DM 
type 2 in other studies152,153. Certainly, the evidence suggests that 
increased arterial stiffness (PWV) and endothelial dysfunction precedes 
the development of DM154.  
While the evidence is clear about the association of DM types 1 and 2 
with increased arterial stiffness, it is uncertain about the relationship with 
AIx. O’Brien and colleagues showed no increase of AIx after controlling for 
HR in a large cohort of patients with DM155. Other studies showed 
heterogeneous results mainly due to the different methods or devices 
used to measure AIx151,156,157.  
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V. PAD: Arterial stiffness prognostic value is poorly studied in patients with 
PAD. Although some studies have shown that patients with PAD have 
stiffer carotid and femoral158 arteries as well as increased aortic 
stiffness159, there are no studies in the literature which evaluate whether 
increased arterial stiffness in this patients’ cohort has any prognostic 
value. In 4159 randomly selected patients in Denmark, AIx had the same 
predictive power as ABPI and CRP160. AIx also predicted patients with 
abnormal ABPI in a study of 475 adults without cardiovascular disease161. 
Additionally, AIx, not PWV, was associated with aortic atherosclerosis in a 
cohort of African American patients who underwent transesophageal 
echocardiography162.  
VI. Drugs:  
i. β-Blockers: Different β-Blockers have different effects on arterial 
stiffness dependent on their receptor affinities. For instance, 
bisoprolol has shown to decrease PWV in the short term163 but 
not in the long term164.  Some β-Blockers also increase AIx by 
decreasing HR and others decrease AIx by decreasing vascular 
tone165. Β-Blockers prolong the cardiac diastolic duration which 
leads to increased coronary perfusion and a decrease in AIx.  
ii. Antioxidants: Vitamin C, E and xanthines such as allopurinol have 
potential positive effects on the cardiovascular system. This is 
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believed to be due to their role in decreasing endothelial 
dysfunction by their action upon nitric oxide (NO) by decreasing its 
degredation by free radicals166-170.  Regarding arterial stiffness, 
vitamin E improved arterial compliance in middle aged men and 
women171 and vitamin C has been associated with a decreased 
arterial stiffness172.    
iii. ACE inhibitors: The effect of ACE inhibitors will be discussed in 
detail in the following section.  
iv. Other antihypertensives: Different antihypertensive agents have 
different effects on arterial stiffness163 which is independent of 
their effect on BP reduction. For example, two antihypertensive 
agents (Fosinopril and atenolol) which reduce BP to a similar 
degree were compared in terms of their effect on AIx. Fosinopril 
reduced AIx more than atenolol173. This is however expected due 
to the effect of atenolol on HR which is considered a disadvantage 
as decreasing HR will result in an increase in AIx. In the CAFE trial, 
AIx and AP decreased to more extent in the amlodipine with or 
without perindopril treatment arm than the atenolol with or 
without thiazide treatment arm174. Klingbeil et al175 have also 
shown that treatment with valsartan reduced AIx more than 
hydrochlorothiazide in a double-blind randomised trial. 
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Introduction 
Several recent trials tested the effect of ACE inhibitors on arterial stiffness as 
measured by PWV and wave reflections as measured by AIx in patients with 
several pathological conditions.  
In this meta-analysis we investigated the effect of ACE inhibitors compared 
with placebo or no treatment on arterial stiffness as measured by PWV and 
on arterial wave reflections as measured by AIx in patients with several 
pathological conditions as a primary outcome measure. We also studied the 
effect of ACE inhibitors compared with other antihypertensive agents: 
Angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), β-
blockers and diuretics on arterial stiffness and wave reflections as a 
secondary outcome measure. As a tertiary outcome measure, we 
investigated this effect when ACE inhibitors are combined with other 
antihypertensive agents and when they are compared to a combination of 
antihypertensive agents.  
Systematic Review and Meta-analysis 
A systematic review was conducted to investigate the effect of ACE inhibitors 
on arterial stiffness assessed by PWV and/or AIx. The literature was searched 
on RCTs that assessed this effect from inception until July 2011 using the 
medical databases: MEDLINE, EMBASE and CENTRAL. In addition, we 
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searched the reference lists of relevant articles to identify articles missed by 
the electronic searches.  
We used the MeSH and free keywords ‘angiotensin converting enzyme 
inhibitors’, ‘angiotensin converting-enzyme inhibitors’, ‘ACE inhibitors’, 
‘arterial stiffness’, ‘pulse wave velocity’, ‘PWV’, ‘augmentation index’, and 
‘AIx’. An expanded search was used using Boolean operators.  
The search was limited to RCTs which were published in English and involved 
humans. It is worth mentioning that we only included studies where the 
minimum treatment period with ACE inhibitor was one month.  
 
Results of Systematic Review and Meta-analysis 
Our analysis included 23 RCTs173,176-197 and 1645 patients. Characteristics of 
trials have been summarized in tables 5 and 6.  
In all trials, major characteristics of patients at baseline were similar between 
study groups. The mean age of patients ranged from 33177 to 69192 years. The 
mean systolic BP ranged from 120177 to 176197 mmHg and the mean diastolic 
BP ranged from 69176 to 105173 mmHg at baseline. Mean follow-up duration 
ranged from 1 month 181,187 to 52 months179. Patients’ characteristics have 
been summarized in table 7.  
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ACE Inhibitors Effect on Carotid-Femoral Pulse Wave Velocity 
ACE Inhibitors vs. Placebo 
Overall, 5 trials176-180 assessed the effect of ACE inhibitors on PWVcf 
compared to placebo. These studies included a total of 469 patients. 227 
patients received ACE inhibitor and 216 patients received placebo. Across the 
5 trials we found insignificant heterogeneity (I²=52%, P=0.060). A fixed effect 
model showed that treatment with ACE inhibitor significantly improved 
PWVcf (Pooled mean change difference=-1.69 m/s, 95% CI -2.05 to -1.33, 
P<0.00001) (Figure 10).  
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Author/Year Country PWV Design Masking Participants 
(n) 
Assessment 
method 
ACEI 
(n)  
Control 
(n)  
ACEI  ACEI  
d/d 
Control Control 
d/d 
ΔSBP 
ACEI 
ΔSBP 
Control 
ΔDBP 
ACEI 
ΔDBP 
Control 
outcome 
ACEI vs. placebo 
Yu/2006 
176 
Taiwan CF Parallel Double 46 Applanation 
tonometry*  
24 22 Ramipril 7.5 mg Placebo ---------- -10 -5 -9 -3 No significant effect 
on PWV 
Ahimastos/ 
2007 
177 
Australia CF, FA Parallel Double 17 Applanation 
tonometry* 
10 7 Perindopril 8 mg Placebo ---------- -4 1 -4 1 Reduced arterial 
stiffness 
Rahman 
A/2007
178 
Malaysia CF Parallel Double 33 SphygmoCor 11 10 Ramipril 5 mg Placebo ---------- -7 -9.9 -6 -5.4 Reduced arterial 
stiffness 
Rahman 
B/2007
178
 
Malaysia CF Parallel Double 33 SphygmoCor 10 9 Ramipril 5 mg Placebo ---------- -13 -3 -9.6 -2.7 Reduced arterial 
stiffness 
Mitchell/ 
2007 
179 
Canada CF Parallel Open 300 Applanation 
tonometry* 
152 148 Trandolapril 4 mg Placebo ---------- NR NR NR NR Modest reduction in 
arterial stiffness 
Ahimastos/ 
2008
180 
Australia CF Parallel Double 40 Applantion 
tonometry* 
20 20 Ramipril 10 mg Placebo ---------- -5.4 -0.5 -6.3 -0.7 Reduced arterial 
stiffness 
ACEI vs. other antihypertensives 
1.ACEI vs. ARB 
Mahmud/ 
2002
181 
Ireland 
 
CF Cross-
over 
Single 12 Complior 12 12 Captopril 100 
mg 
Valsartan 160 mg -19 -23 -13 -13 Both treatments 
reduced arterial 
stiffness 
Rajzer 
/2003
182 
Poland CF Parallel Open 118 Complior 38 24 Quinapril 20 mg Losartan 100 mg -41 -30 -11 -7 PWV decreased only 
under Quinapril 
Rehman/ 
2007
183 
Malaysia CF Parallel Double 39 Complior 20 19 Perindopril 4 mg Losartan 50 mg -18 -14 -9 -8 PWV decreased 
under both 
Ali/2009
184 
UK CF, CR, 
FD 
Cross-
over 
Double 15 Complior 15 15 Lisinopril 20 mg Irbesartan 300 mg -17.2 -27.9 -14.6 -20.1 PWV decreased 
under both 
2. ACEI vs. CCB 
London/ 
1994
185 
France CF Parallel Single 32 Applanation 
tonometry* 
14 10 Perindopril 4 mg Nitrendipi
ne 
40 mg -26 -19.6 -14.9 -9.8 PWV decreased 
under both  
Rajzer 
/2003
182 
Poland CF Parallel Open 118 N/A 38 37 Quinapril 20 mg Amlodipin
e 
10 mg -41 -27 -11 -9 PWV decreased only 
under Quinapril 
Mackenzie/ 
2009
186 
UK CF Parallel Double 59 SphygmoCor 15 14 Perindopril 4 mg Lercanidipi
ne 
10 mg -17 -13 -5 -1 PWV did not change 
by any  
3.ACEI vs. β-blocker 
Pannier/ 
2001
187 
France CF Cross-
over 
Double 20 Complior 20 20 Perindopril 8 mg Atenolol 100 mg -13.8 -16.5 -9.6 -10.3 PWV decreased 
under both  
Mackenzie/ 
2009
186 
UK CF Parallel Double 59 N/A 15 17 Perindopril 4 mg Atenolol 50 mg -17 -18 -5 -8 PWV did not change 
under both 
        
     Table 5: Studies investigating ACE inhibitors effect on PWV 
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Author/Year Country PWV Design Masking Participants 
(n) 
Assessment 
method 
ACEI 
(n)  
Control 
(n)  
ACEI  ACEI  
d/d 
Control Control 
d/d 
ΔSBP 
ACEI 
ΔSBP 
Control 
ΔDBP 
ACEI 
ΔDBP 
Control 
outcome 
4. ACEI vs. Diuretic 
Breithaupt-
Grogler/ 
1996
188 
Germany CF Parallel Double 17 Applanation 
tonometry* 
9 8 Cilazapril 5 mg Hydrochlo
ro-thiazide 
25 mg -11 -25 -11 -17 PWV decreased 
under both 
Mackenzie 
/2009
186
  
UK CF Parallel Double 59 N/A 15 13 Perindopril 4mg Bendroflu-
azide 
2.5 mg -17 -14 -5 -3 No change in PWV 
under both 
Kostka-
Jeziorny/ 
2011
189 
Poland CF Parallel Open 66 Complior 35 31 Perindopril 10 mg Hydrochlo
ro-thiazide 
25 mg -23 -24 -14 -13 PWV decreased only 
under Perindopril 
5. ACEI vs. ACEI and ARB 
Mahmud/ 
2002
181 
Ireland CF Cross-
over 
Single 12 N/A 12 12 Captopril 100 mg Captopril  
Valsartan 
100mg 
160mg 
-19 -28 -13 -18 PWV decreased 
more under 
combined therapy  
ACEI and other antihypertensives vs. other antihypertensives 
Asmar 
/2001
196 
France CF Parallel Double 406 Complior 204 202 Perindopril 
Indapamide 
2mg 
0.625mg 
Atenolol 50mg -23.1 -16.2 -13.3 -12.9 PWV decreased 
under both to a 
similar degree 
 
Table 5 (Continued): CF: Carotid-femoral, CR: Carotid-radial, FA: Femoral-ankle, FD: Femoral-dorsalis pedis, ARB: Angiotensin receptor blocker, CCB: 
Calcium channel blocker, N/A: Not applicable as reported elsewhere in the table, d/d: Dose per day, *Studies which measured PWV using sequential 
applanation tonometry without mentioning the name of the device used 
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Author/ Year Country Design Masking Participants 
(n) 
Assessment 
method 
ACEI 
(n)  
Control 
(n)  
ACEI  ACEI  
d/d 
Control Control 
d/d 
ΔSBP 
ACEI 
ΔSBP 
Control 
ΔDBP 
ACEI 
ΔDBP 
Control 
ΔHR 
ACEI 
ΔHR 
Control 
outcome 
ACEI vs. placebo 
Dart/2001
190 
Australia Parallel Open 111 PWV 
Medical BP 
Analysis 
System 
50 61 Perindopril 8 
mg 
Usual 
treatment 
----------  -13 -7 -10 -4 3 -1 Perindopril 
reduced AIx 
Deary/2002
191
  UK Cross-
over 
Double 30 SphygmoCor 30 30 Lisinopril 10 
mg 
Placebo ---------- -15♂ 
-21♀ 
0 
0 
-11 
-9 
0 
0 
1 
1 
0 
0 
Lisinopril 
reduced AIx 
Tsang/2006
192 
USA Parallel Double 21 SphygmaCor 9 12 Quinapril 60 
mg 
Placebo ---------- -12 -9 NR NR NR NR Quinapril 
reduced AIx 
Yu/2006 
176 
Taiwan Parallel Double 46 Applanation 
tonometry* 
24 22 Ramipril 7.5 
mg 
Placebo ---------- -10 -5 -9 -3 3 0 No 
significant 
effect on AIx 
Rahman A/2007
178 
Malaysia Parallel Double 33 SphygmoCor 11 10 Ramipril 5 
mg 
Placebo ---------- -7 -9.9 -6 -5.4 1.5 1.4 Ramipril 
reduced AIx 
Rahman B/2007
178 
Malaysia Parallel Double 33 SphygmoCor 10 9 Ramipril 5 
mg 
Placebo ---------- -13 -3 -9.6 -2.7 9.8 2.7 Ramipril 
reduced AIx 
Mitchell/2007
179 
Canada Parallel Open 300 Applanation 
tonometry* 
152 148 Trando-
lapril 
4 
mg 
Placebo ---------- NR NR NR NR NR NR Trandolapril 
reduced AIx 
Ahimastos/2008
180 
Australia Parallel Double 40 Applanation 
tonometry* 
20 20 Ramipril 10 
mg 
Placebo ---------- -5.4 -0.5 -6.3 -0.7 NR NR Ramirpil 
reduced AIx 
ACEI vs. other antihypertensives 
1.ACEI vs. ARB 
Mahmud/2002
181 
Ireland 
 
Cross-
over 
Single 12 SphygmoCor 12 12 Captopril 100 
mg 
Valsartan 160 mg -19 -23 -13 -13 -1 0 AIx decreaed 
under both 
2. ACEI vs. CCB 
Deary/2002
191 
UK Cross-
over 
Double 30 N/A 30 30 Lisinopril 10 
mg 
Amlodipine 5 mg -15♂ 
21♀ 
-9 
-26 
-11 
-9 
-8 
-5 
1 
1 
3 
-1 
AIx 
decreased 
under both 
Mackenzie/2009
186 
UK Parallel Double 59 SphygmaCor 15 14 Perindopril 4 
mg 
Lercani-
dipine 
10 mg -17 -13 -5 -1 2 2 Lercanidipine 
reduced AIx 
more than 
Perindopril 
3.ACEI vs. β-blocker 
Chen/1995
173 
China Parallel Double 79 Applanation 
tonometry* 
41 38 Fosinopril 20 
mg 
Atenolol 100 mg -23 -28 -14 -16 1 -15 Fosinopril 
reduced AIx 
more than 
Atenolol 
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Author/ Year Country Design Masking Participants 
(n) 
Assessment 
method 
ACEI 
(n)  
Control 
(n)  
ACEI  ACEI  
d/d 
Control Control 
d/d 
ΔSBP 
ACEI 
ΔSBP 
Control 
ΔDBP 
ACEI 
ΔDBP 
Control 
ΔHR 
ACEI 
ΔHR 
Control 
outcome 
Pannier/2001
187 
France Cross-
over 
Double 20 SphygmoCor 20 20 Perindopril 8 mg Atenolol 100 mg -13.8 -16.5 -9.6 -10.3 -0.5 -10.2 AIx decreased 
significantly 
under 
Perindopril 
Deary/2002
191 
UK Cross-
over 
Double 30 N/A 30 30 Lisinopril 10 mg Bisoprolol 5 mg -15♂ 
-21♀ 
-19 
-21 
-11 
-9 
-11 
-12 
1 
1 
 
-8 
-14 
Only Lisinopril 
reduced AIx 
Neal/2004
193 
UK Cross-
over 
Double 12 SphygmoCor 12 12 Lisinopril 20 mg Bisoprolol 20 mg -24 -12 -11 -7 -1 -19 Lisinopril only 
reduced AIx 
Kaiser/2006
194 
Germany Cross-
over 
Double 10 SphygmoCor 10 10 Enalapril 10 mg Nebivolol 5 mg -15 -17 -7 -6 NR NR No significant 
difference 
between both  
Mackenzie/2009
186 
UK Parallel Double 59 N/A 15 17 Perindopril 4 mg Atenolol 50 mg -17 -18 -5 -8 2 -10 AIx decreased 
only under 
Perindopril 
4.ACEI vs. diuretic 
Deary/ 
2002
191 
UK Cross-
over 
Double 30 N/A 30 30 Lisinopril 10 mg Bendroflu-
azide 
2.5 mg -15♂ 
-21♀ 
-6 
-19 
-11 
-9 
-3 
-4 
1 
1 
1 
0 
AIx decreased 
only under 
Lisinopril 
Jiang/2007
195 
China 
 
Parallel Double 101 SphygmoCor 51 50 Enalapril 10 mg Indapa-
mide 
2.5 mg -16.9 -14 -9.9 -7.8 -0.5 0.6 Only Enalapril 
decreased AIx 
Mackenzie/2009
186 
 
 
UK Parallel Double 59 N/A 15 13 Perindopril 4mg Bendroflu-
azide 
2.5 mg -17 -14 -5 -3 2 2 Perindopril 
reduced AIx 
more than 
Bendrofluazide 
5. ACEI vs. ACEI and ARB 
Mahmud/ 
2002
181 
Ireland Cross-
over 
Single 12 N/A 12 12 Captopril 100mg Captopril 
Valsartan 
100mg 
160mg 
-19 -28 -13 -18 -1 -1 AIx decreased 
more under 
combination 
therapy 
ACEI and other antihypertensives vs. other antihypertensives  
1. ACEI & diuretic vs. β-blocker 
Asmar/ 
2001
196 
France Parallel Double 406 Applanation 
tonometry* 
65 64 Perindopril 
Indapa-
mide 
2mg 
0.625mg 
Atenolol 50mg -23.1 -16.2 -13.3 -12.9 -1.4 -7.8 AIx decreased 
more under 
ACEI & diuretic 
 
ACE Inhibitors Effect on Arterial Stiffness                                                                                                 Chapter 4                                                                                
 
88 
 
Author/ 
Year 
Country Design Masking Participants 
(n) 
Assessment 
method 
ACEI 
(n)  
Control 
(n)  
ACEI  ACEI  
d/d 
Control Control 
d/d 
ΔSBP 
ACEI 
ΔSBP 
Control 
ΔDBP 
ACEI 
ΔDBP 
Control 
ΔHR 
ACEI 
ΔHR 
Control 
outcome 
2. ACEI & diuretic vs. CCB 
Ferguson/ 
2008
197 
Australia Cross-
over 
Double 28 SphygmoCor 22 22 Fosinopril 
HCT 
20mg 
12.5 
mg 
Amlodipine 10mg -22 -16 -9.2 -5 NR NR AIx 
decreased 
more with 
combination 
therapy 
3. ACEI & diuretic vs. diuretic 
Ferguson/ 
2008
197 
Australia Cross-
over 
Double 28 SphygmoCor 22 22 Fosinopril 
HCT 
20mg 
12.5 
mg 
Indapa-
mide 
2.5mg -22 -23 -9.2 -8 NR NR AIx 
decreased 
more with 
combination 
therapy 
 
Table 6: Studies investigating ACE inhibitors effect on AIx. CCB: Calcium channel blocker, ARB: Angiotensin receptor blocker, ♂: Male, ♀: Female, HCT: 
Hydrochlorothiazide, N/A: Not applicable, NR: Not reported, d/d: Dose per day, * Studies which measured AIx using sequential applanation tonometry without 
mentioning the name of the device used 
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Author/Year Patients Mean Age,y Male 
 n (%) 
Mean SBP Mean DBP MAP Diabetes Mellitus n(%) Follow-up 
Months 
Yu/2006
176 
ESRD 47 30(65) 123 69 NR 3(7) 12 
Ahimastos/2007
177 
Marfan’s  33 14(82) 120 72 82 0(0) 6 
Rahman/2007
178 
DM type 2, IGT 47 NR 126 80 NR 33(50) 12  
Mitchell/2007
179 
CAD 63 271(90) 133 79 97 26(9) 52 
Ahimastos/2008180 PAD 66 38(95) 140 87 92 0(0) 6 
Mahmud/2002
181 
Hypertension 49 NR 157 96 NR NR 1 
Rajzer/2003
182 
Hypertension 54 54(46) 154 97 116 NR 6 
Rehman/2007
183 
Hypertension 52 NR 151 93 NR NR 4 
Ali/2009
184 
Hypertension 66 NR 162 99 NR NR 3 
London/1994185 ESRD 53 14(44) 176 98 124 NR 12 
Mackenzie/2009186 Hypertension 68 31(53) 159 84 107 NR 2.5 
Pannier/2001187 Hypertension 49 13(65) 164 99 NR NR 1 
Breithaupt-Grogler/1996188 Hypertension 45-67 NR 150 99 121 NR 3 
Kostka-Jeziorny/2011189 Hypertension 46 40(61) 157 97 NR 0(0) 2 
Dart/2001190 Hypertension 60 53(48) 147 88 NR NR 3 
Deary/2002191 Hypertension 47 22(73) 157 99 NR NR 1.5 
Tsang/2006192 DD 69 10(48) 127 71 NR 0(0) 12 
Chen/1995173 Hypertension 45.8 52(66) 151 105 NR NR 2 
Neal/2004193 Transplant 60 6(46) 154 92 114 0(0) 3 
Kaiser/2006
194 
DM type 2 62 7(70) 155 90 NR 10(100) 3 
Jiang/2007195 Hypertension 54 55(54) 155 95 NR NR 2 
Asmar/2001196 Hypertension NR NR 162 99 119 NR 12 
Ferguson/2008
197 
Hypertension 62 14(50) 164 86 NR 0(0) 2 
  
Table 7: Patients’ characteristics. SBP: Systolic blood pressure, DBP: Diastolic blood pressure, MAP: Mean arterial pressure, ESRD: End-stage renal disease, 
DM: Diabetes mellitus, CAD: Coronary artery disease, PAD: Peripheral arterial disease, DD: Diastolic dysfunction, NR: Not reported 
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ACE Inhibitors vs. Other Antihypertensives 
9 trials 181-189 which included 378 patients assessed the effect of ACE 
inhibitors (n=178) versus other antihypertensives (n=220) including: ARBs, 
CCBs, β-blockers, diuretics and a combination of ACE inhibitor and ARBs. 
Compared with other antihypertensive agents, ACE inhibitors insignificantly 
reduced PWVcf (Pooled mean change difference= -0.19 m/s, 95% CI -0.59 to 
0.21, P=0.360, I²= 0%) (Figure 11).  
 
ACE Inhibitors vs. ARBs 
4 trials 181-184 which included 184 patients assessed the effect of ACE 
inhibitors (n=85) versus ARBs (n=70) on PWVcf. ACE inhibitors showed no 
significant effect on PWVcf when compared with ARBs (Pooled mean change 
difference = -0.36 m/s, 95% CI -0.92 to 0.20, P=0.210, I²=0%) (Figure 11).  
 
ACE Inhibitors vs. CCBs 
ACE inhibitors effect compared with CCBs effect on PWVcf was evaluated in 3 
trials182,185,186. Studies included a total of 209 patients. ACE inhibitors (n=67) 
showed insignificant effect on PWVcf when compared with CCBs (n=61) 
(Pooled mean change difference = -0.62 m/s, 95% CI -2.37 to 1.13, P=0.490, 
I²=0%) (Figure 11).  
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ACE Inhibitors vs. β-Blockers  
2 trials 186,187  which included 79 patients evaluated the effect of ACE 
inhibitors (n=35) versus β-blockers (n=37) on PWVcf. Treatment with ACE 
inhibitors showed no significant effect on PWVcf when compared with β-
blockers (Pooled mean change difference= 0.44 m/s, 95% CI -0.69 to 1.57, 
P=0.440, I²=0%) (Figure 11). 
  
ACE Inhibitors vs. Diuretics  
3 trials186,188,189 which included 142 patients evaluated the effect of ACE 
inhibitors versus diuretics on PWVcf. Treatment with ACE inhibitors 
insignificantly reduced PWVcf compared to diuretics (Pooled mean change 
difference= -0.69 m/s, 95% CI -1.6 to 0.21, P=0.130, I²=0%) (Figure 11).  
 
 ACE Inhibitors vs. ACE Inhibitors and ARBs  
One RCT 181 which included 12 patients assessed the effect of ACE inhibitor 
versus a combination of ACE inhibitor and ARB on PWVcf. Treatment with 
ACE inhibitor and ARB insignificantly reduced PWVcf when compared to ACE 
inhibitor alone (Mean change difference= -1 m/s, 95% CI -2.2 to 0.2, P=0.100) 
(Figure 11).  
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ACE Inhibitors Combined with Other Antihypertensive Agents vs. 
Other Antihypertensive Agents  
 
ACE Inhibitor and Diuretic vs. β-Blocker 
Asmar et al196 evaluated the effect of ACE inhibitor combined with a diuretic 
versus β-blocker. Treatment with β-blocker insignificantly reduced PWVcf 
more than a combination of ACE inhibitor and diuretic (Mean change 
difference=-0.19 m/s, 95% CI -0.14 to 0.53, P=0.260).  
 
 
 
Figure 10: Forest plot illustrating ACE Inhibitors effect on changes in PWVcf compared with 
placebo. The x-axis is in m/sec. Small squares represent the differences in mean changes in 
PWVcf across individual studies between study groups (ACE Inhibitor minus placebo or no 
treatment). The 95 per cent confidence intervals for individual studies are represented by a 
horizontal line and by a diamond for pooled effect. CI: Confidence interval, SE: Standard 
error, IV: Inverse variance 
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Figure 11: Forest plot illustrating ACE inhibitor effect on changes in PWVcf compared with 
other antihypertensive agents. For further detail see legend for figure 11. ARB: Angiotensin 
receptor blocker, CCB: Calcium channel blocker, CI: Confidence interval, SE: Standard error, 
IV: Inverse variance 
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ACE Inhibitors Effect on Augmentation Index 
 
ACE Inhibitors vs. Placebo 
7 trials 176,178-180,190-192 assessed the effect of ACE Inhibitors on AIx versus 
placebo. These studies included 614 patients. 306 patients received ACE 
inhibitor and 312 patients received placebo or their usual treatment. 
Treatment with ACE inhibitor significantly reduced AIx when compared to 
placebo or usual treatment (Pooled mean change difference=-3.79%, 95% CI -
5.96 to -1.63, P=0.0006, I²=87%, P for heterogeneity < 0.00001) (Figure 12).  
 
ACE Inhibitors vs. Other Antihypertensives 
8 trials173,181,186,187,191,193-195 which included 323 patients evaluated the effect 
of ACE inhibitors versus other antihypertensives. Treatment with ACE 
inhibitor significantly reduced AIx compared to other antihypertensives as a 
whole (Pooled mean change difference= -1.84%, 95% CI -3 to-0.68, P=0.002) 
with insignificant heterogeneity (I²=32%, P=0.110) (Figure 13).  
 
ACE Inhibitors vs. ARBs 
ACE inhibitors effect on AIx compared with ARBs was only assessed in one 
trial 181 which included 12 patients. Treatment with ACE inhibitor showed no 
significant effect on AIx when compared with ARB (Pooled mean change 
difference=-3%, 95% CI -25.54 to 19.54, P=0.790) (Figure 13).  
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ACE Inhibitors vs. CCBs 
Two trials 186,191  which included 89 patients evaluated the effect of ACE 
inhibitors compared to CCBs on AIx. Treatment with ACE inhibitors showed 
no significant effect on AIx when compared to CCBs (Pooled mean change 
difference= -2.96%, 95% CI -8.54 to 2.63, P=0.300) with no heterogeneity 
(Figure 13).   
 
ACE Inhibitors vs. β-Blockers 
6 trials173,186,187,191,193,194 assessed the effect of ACE inhibitors on AIx 
compared to β-blockers. Treatment with ACE inhibitors significantly reduced 
AIx when compared with β-blockers (Pooled mean change difference= -1.6%, 
95% CI -2.84 to -0.36, P=0.010) with significant heterogeneity (I²=67%, 
P=0.006) (Figure 13).  
 
ACE Inhibitors vs. Diuretics 
ACE inhibitors effect on AIx compared to diuretics was assessed in 3 
trials186,191,194. Treatment with ACE inhibitors showed no significant effect on 
AIx when compared to diuretics (Pooled mean change difference= -4.1%, 95% 
CI -8.3 to 0.1, P=0.060) with no heterogeneity (Figure 13).  
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ACE Inhibitors vs. ACE Inhibitors and ARBs 
One RCT181 which included 12 patients assessed the effect of ACE inhibitor 
versus a combination of ACE inhibitor and ARB on AIx. Treatment with ACE 
inhibitor and ARB significantly reduced AIx when compared to ACE inhibitor 
(Pooled mean change difference= -3%, 95% CI -22.4 to 16.4, P= 0.760) (Figure 
13).  
 
ACE Inhibitors Combined with Other Antihypertensive Agents vs. 
Other Antihypertensive Agents  
 
ACE Inhibitors and Diuretics vs. Other Antihypertensive Agents 
Overall, 2 trials 196,197 evaluated the effect of ACE inhibitors combined with 
diuretics versus other antihypertensive agents on AIx. The combination 
therapy significantly reduced AIx when compared with other 
antihypertensives as a whole (Pooled mean change difference= -4.68%, 95% 
CI -7.94 to -1.78, P=0.002) with no heterogeneity (Figure 14).  
 
ACE Inhibitor and Diuretic vs. β-Blocker  
ACE inhibitor combined with a diuretic versus β-blocker was assessed in one 
RCT196. Treatment with a combination of ACE Inhibitor and diuretic 
significantly reduced AIx when compared to β-blocker (Mean change 
difference=-5.57%, 95% CI -10.77 to -0.36, P=0.040) (Figure 14).  
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ACE Inhibitor and Diuretic vs. CCB  
Ferguson et al197 assessed the effect of ACE inhibitor combined with diuretic 
versus CCB on AIx. The combined treatment significantly reduced AIx 
compared to CCB (Mean change difference=-6.5%, 95% CI -12.7 to -0.22, 
P=0.040) (Figure 14).  
 
ACE Inhibitor and Diuretic vs. Diuretic 
Ferguson et al197 also assessed the effect of a combination therapy of ACE 
inhibitor and diuretic versus diuretic on AIx. The combination therapy 
insignificantly reduced AIx when compared to diuretic alone (Mean change 
difference=-3.2%, 95% CI -8.1 to 1.7, P=0.200) (Figure 14).  
 
 
 
Figure 12: Forest plot illustrating ACE inhibitors effect on changes in AIx compared with 
placebo or usual treatment. The x-axis is in percentage (%). For further detail see legend for 
figure 11. CI: Confidence interval, SE: Standard error, IV: Inverse variance  
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Figure 13: Forest plot illustrating ACE inhibitors effect on changes in AIx compared with 
other antihypertensive agents. For further detail see legend for figure 11. ARB: Angiotensin 
receptor blocker, CCB: Calcium channel blocker, CI: Confidence interval, SE: Standard error, 
IV: Inverse variance  
 
 
 
 
ACE Inhibitors Effect on Arterial Stiffness            Chapter 4                                                                                                                                                            
 
99 
 
 
 
Figure 14: Forest plot illustrating the effect of a combination therapy of ACE inhibitor and 
diuretic compared with other antihypertensive agents on AIx. For further detail see legend 
for figure 11. CCB: Calcium channel blocker, CI: Confidence interval, SE: Standard error, IV: 
Inverse variance 
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Discussion of Systematic Review 
The main finding of this extensive systematic review and meta-analysis on 
the effect of ACE inhibitors on arterial stiffness is that treatment with ACE 
inhibitors in patients with arterial stiffness caused by different pathological 
conditions improved the stiffening of the arteries as assessed by PWVcf and 
reduced arterial wave reflections as assessed by AIx when compared with 
placebo. Furthermore, ACE inhibitors significantly reduced AIx and 
insignificantly PWVcf when compared with other antihypertensive agents as 
a whole. ACE inhibitors were not superior to ARBs, CCBs, β-blockers and 
diuretics in their effect on PWVcf when compared separately and as a whole. 
However, their effect on AIx was superior to the combined effect of other 
antihypertensives but only superior to β-blockers when compared separately. 
Furthermore, there is lack of evidence regarding trials assessing the effect of 
ACE inhibitors on arterial stiffness in patients with PAD with only one RCT 
assessing this effect180. Ahimastos and colleagues180 assessed arterial 
stiffness using the ultrasound method which is not the gold standard. Their 
study also was limited to non-diabetic patients with infrainguinal disease 
which limits their findings. Hence, the need for further trials to confirm the 
effect of ACE inhibitors on arterial stiffness in patients with PAD.
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5.1 Hypotheses Testing 
The role of the ACE inhibitor, ramipril, in reducing cardiovascular morbidity 
and mortality and health economic analysis of cost effectiveness in patients 
with PAD with no evidence of left ventricular dysfunction or heart failure is 
supported by level-1 evidence. However, the evidence regarding the effect of 
ramipril on walking distance in patients with IC is limited with only one 
published randomised controlled trial which was limited to non-diabetic 
patients with infrainguinal disease. Additionally, there are no published 
randomised controlled trials evaluating this effect on quality of life (QoL) in 
patients with IC.   
Therefore, through a double blind, randomised, placebo controlled clinical 
trial; we aim to test the following hypotheses:  
Hypothesis (1):  ACE inhibitor improves clinical indicators of lower limb 
ischaemia in patients with IC. 
Hypothesis (2): ACE inhibitor improves arterial stiffness and wave reflections 
in patients with IC. 
Hypothesis (3): ACE inhibitor improves cardiovascular prognosis in patients 
with IC.   
Hypothesis (4): ACE inhibitor improves biochemical markers of inflammation 
and ischemia reperfusion in patients with IC. 
Hypothesis (5): ACE inhibitor improves generic and disease specific QoL in 
patients with IC.  
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5.2 Study Design 
A double blind, randomised, placebo controlled clinical trial of two way 
design with participants randomised to placebo group or ramipril group. 
  
5.3 Sample Size 
Based on a previous RCT109 which was done to examine the effects of ACE 
inhibitor on walking in patients with PAD, 40 patients were randomised to 
achieve a power of 86%.   Therefore, to detect a change of 150 meters MWD 
with ramipril, with a 5% two tailed significance level assuming a pooled 
standard deviation (SD) of 125 metres, 12 patients in each group (a total of 
24 patients) will achieve a power of 96%. However, with an estimate of 30% 
loss to follow up/withdrawals, we aimed to recruit a total of 32 patients.   
 
5.4  Assessment of Eligibility 
 
Inclusion Criteria 
 Patients with unilateral or bilateral intermittent leg claudication which 
was stable for the last 6 months. 
 Patients with ABPI < 0.9 at rest at least in one leg. 
 BP ≤ 160/90 and a stable medication regimen for the last 6 months. 
 Able to give informed consent 
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 Able to comply with study protocol 
 
 Exclusion Criteria 
 Documented bilateral renal artery stenosis 
 Unlikely to be compliant with medication or follow up as determined by 
the recruiting institution 
 Pregnancy and breast feeding 
 Women of child bearing age not having a method of contraception 
 Patients with critical limb ischemia (This includes patients with ischaemic 
rest pain and ulceration > 2 weeks and/or a resting ankle pressure < 
50mmHg- Grades II and III according to Rutherford et al 1997198 
 Patients who had a recent (less than 3 months) angioplasty or bypass 
surgery 
 Patients who are unable to perform a treadmill test due to a limiting 
heart, respiratory or arthritic disease 
 History of angioneurotic oedema 
 Currently taking ACE inhibitor or Angiotensin receptor blocker 
 Contraindication to ACE inhibitor 
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 History of ACE inhibitor intolerance 
 A creatinine rise of > 30% from baseline and/or Potassium > 5.9 mmol/l 
 Unwillingness to participate 
 Level 1 evidence for ACE inhibitor treatment, including: 
a. Documented heart failure, left ventricular dysfunction or ejection fraction 
<35% on previous echocardiography 
b. Uncontrolled hypertension, BP > 160mmHg systolic or 100mmHg diastolic 
on 3 separate readings measured after 10 minutes rest on 2 separate 
occasions 
c. Recent (< 3months) myocardial infarction or stroke 
d. Chronic renal impairment (serum creatinine > 250 mmol/l).  
 
5.5  Randomisation 
Patients were randomised to receive either placebo or ramipril. 
Randomisation was undertaken by pharmacy department at Hull Royal 
Infirmary and was done through a computer generated blocks of 10s. At 
randomisation participants were given a unique identification number to be 
used for identification purposes through-out the trial. 
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5.6  Trial Phases 
 
‘Run in’ Phase 
 
All consenting patients undertook a ‘run in’ phase prior to randomisation, in 
which they received ramipril 2.5mg orally o.d. for 1 week, increased to 5mg 
orally o.d. for a further week. At the end of each week clinical status, adverse 
events (dizziness, symptomatic hypotension, cough), drug compliance, BP, 
and renal function were assessed. At this stage participants were excluded if 
they were non-compliant (< 60% of medication taken), suffered disabling side 
effects, demonstrated significant deterioration in renal function (A creatinine 
rise of >30% from baseline, potassium > 5.9mmol/l) or withdrew consent. 
Patients then had a 2-week wash out period.  
 
Randomisation Phase  
 
After the washout period, patients willing to continue the trial were 
randomised on a 1:1 ratio into one of the following groups:  
 Placebo group 
 Ramipril group: Patients will be given Ramipril 5 mg once daily for 2 
weeks increased to 10 mg once daily for 22 weeks. 
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5.7 Trial Treatments  
Ramipril and placebo were encapsulated and identical in shape. Study 
medication was stored and dispensed by the trial site’s pharmacy 
department in accordance with Good Clinical Practice and Good 
Manufacturing Practice. At the ‘run in’ phase, each patient was dispensed 
one container of 7 capsules of ramipril 2.5 mg for a week and one container 
of 7 capsules of ramipril 5 mg for another week at another visit. 
At the randomisation phase each patient was dispensed one container which 
had 14 capsules of either ramipril 5 mg or placebo for 14 days and another 
container which had 154 capsules of either Ramipril 10 mg or placebo for 154 
days at another visit. 
Each container was tamper evident and child resistant. All containers were 
labelled with a double blind label printed in black ink. The label included the 
protocol number, drug name written as ‘ramipril/placebo’, subject number, 
container quantity, storage conditions, expiration date, randomisation or run 
in phase and investigator’s name. Code break envelopes were also provided 
and were kept in pharmacy. 
 
5.8 Double Blinding 
Both patients and the principal investigator were blinded to study 
treatments. The dispensing pharmacists were also blinded to study 
treatments.  
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5.9 Trial Follow-up  
Patients were followed up at 2 weeks, 6 weeks and 24 weeks using the trial 
specific proforma.  
 
5.10 Trial Outcome Measures 
Primary Outcome Measure 
The primary outcome measure for this trial is the treadmill MWD.  
 
Secondary Outcome Measures 
 
Other Clinical Indicators of Lower Limb Ischaemia 
a) Patient Reported Walking Distance (PRWD) 
b) Treadmill ICD or the distance associated with the onset of claudication 
pain measured on the same standardised treadmill test 
c) ABPI at rest (ABPI- r) and following treadmill testing (ABPI – t) 
 
QoL 
a) Generic – measured using the SF36 and EuroQol (EQ5D) instruments 
b) Disease specific – measured using the King’s college VascuQol 
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Biomarkers of Inflammation, Ischaemia Reperfusion and Cardiovascular 
Prognosis  
a) CRP 
b) Fibrinogen 
c) Urine Albumin Creatinine Ratio (UACR) 
d) N-terminal pro B-type natriuretic peptide (NTproBNP) 
 
Arterial Effects   
a) Arterial stiffness by measuring PWV 
b) Wave reflections by measuring AIx 
 
5.11 Trial tests  
 
Blood Pressure Measurement 
BP was measured from each arm at both seated and supine positions at every 
visit using an automated oscillometric device (Welch Allyn, Arden, NC, USA). 
This device has been validated in terms of BP measurement in several 
previous studies199-201.  
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Ankle Brachial Pressure Index Measurement 
ABPI measurement is a simple method of quantifying the severity of arterial 
occlusion in the leg and was first described in 1968 202. The index is measured 
by measuring the maximum systolic BP at the ankle using a hand-held 
Doppler (Recording the highest of either dorsalis pedis (Figure 16) or 
posterior tibial artery (Figure 17)) and dividing this by the highest value of 
systolic pressure recorded from the right and the left brachial arteries. In a 
healthy person, ABPI is > 1.0. ABPI between 0.5 and 0.95 is indicative of PAD 
or IC. ABPI <0.5 is indicative of critical limb ischaemia.  ABPI is considered an 
independent predictor of cardiovascular events203 and a low ABPI is 
associated with increased all-cause and cardiovascular mortality, MI and 
stroke 204-212.  
 
ABPI Measurement Technique Using Doppler  
Patients were asked to rest in a supine position for 5 minutes to allow BP to 
settle. A cuff was placed around the upper arm and the brachial pulse was 
located. Ultrasound gel was then applied and a highly sensitive 8 MHz 
Doppler probe (Parks Medical Electronics, Inc. Aloha, Oregon, USA) was 
placed over the brachial pulse. The cuff was then inflated until the signal 
disappeared and deflated until the systolic signal was regained. The same 
procedure was performed on the opposite arm and the higher of the two 
values was recorded as the systolic bBP. The same procedure was performed 
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to obtain ankle systolic pressure with the cuff placed above the malleoli after 
locating the dorsalis pedis pulse and then repeated for the posterior tibial 
pulse with the higher of the two values recorded. In order to obtain ABPI, this 
value was then divided by the brachial systolic pressure. ABPI of the most 
symptomatic leg was entered into analysis. ABPI was measured at rest and 
after undertaking a treadmill exercise test. Patients underwent ABPI 
measurements at baseline, 2 weeks, 6 weeks and 24 weeks.  
 
 
Figure 15: Detecting dorsalis pedis artery pulse using hand-held Doppler  
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Figure 16: Detecting posterior tibial artery pulse using hand-held Doppler  
 
Treadmill Exercise Test 
Treadmill exercise testing is mainly used for patients with PAD with a normal 
resting ABPI such as patients with iliac artery disease where a significant drop 
in ABPI post exercise is diagnostic of PAD. However, it has been shown that 
walking impairment is a strong predictor of long term outcome in patients 
with impaired ABPI and normal ABPI213.  
 
Treadmill Exercise Test Protocol   
Patients underwent treadmill exercise testing at a speed of 1.6 mph with a 10 
degree incline and for a maximum of 10 minutes according to a standard 
constant-loading protocol in our laboratory. The limitations of this protocol 
are discussed in the limitation of the study section of this thesis. Patients 
were asked to walk on the treadmill to familiarize them with the test during 
the ‘run in’ phase of the trial before conducting a formal test in the 
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‘randomization phase’. Furthermore, patients were given clear verbal 
instructions to what exactly expected of them during conducting a treadmill 
exercise test. Patients’ familiarization with the treadmill exercise test is 
important to reduce interventional bias in the trial. Patients were also 
instructed to avoid walking long distances before their lab visit to avoid 
claudication, avoid smoking or drinking alcohol and wear comfortable 
clothes. During the test, patients were asked not to hold onto the treadmill 
bars for support or off-loading as this will alter patients’ performance and 
introduces variability in the test. The timing device used to record walking 
time was hidden from patients to avoid introducing bias in their 
performance.   ICD was defined as the distance patients with IC can walk until 
they start experiencing pain in the affected leg. MWD was defined as the 
maximum treadmill walking distance that patients with IC can walk until they 
are unable to walk anymore.  
Pule Wave Velocity and Augmentation Index Measurement    
PWV was calculated between the carotid and femoral arteries (PWVcf) as this 
measurement technique is considered by many to be the gold standard of 
PWV measurement214.      Several devices are available in the market for PWV 
measurement including: The SphygmoCor (AtCor Medical Pvt. Ltd, Sydney, 
Australia), the Complior (Artech Medical, Pantin, France), PulsePen 
(DiaTence, Milan, Italy) and most recently the Vicorder (Skidmore Medical, 
Bristol, UK). The SphygmoCor system, which is considered the gold standard, 
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uses sequential applanation tonometry of the arterial waveform with 
electrocardiogram (ECG) gating. It is easily applied and has been widely used 
in adults with excellent reproducibility215,216. The Complior system, on the 
other hand, uses mechanotransducers to detect the pressure waveforms and 
allows simultaneous recordings. The latter two devices have shown 
differences in PWV values when compared with each other mainly due to 
differences in the methods used to measure transit time rather than in the 
methods used to acquire the waveforms217,218. Nevertheless, to date, there is 
no agreement to which device is more accurate in terms of PWV 
measurement219.   
SphygmoCor Device  
The SphygmoCor (Model SCOR-Pvx, software version 8; AtCor Medical Pvt. 
Ltd, Sydney, Australia) was used for PWVcf measurements (Figure 18). It uses 
the applanation tonometry technique to acquire the pulse waveform using 
one tonometric Miller transducer. In order to obtain the PWVcf, the carotid 
and femoral pulse waveforms are recorded sequentially using the transducer 
(Figures 19 and 20) and at the same time an ECG is recorded (Figure 21) as a 
reference to calculate tt using the foot-to-foot method.  The distance the 
pulse waveform travels between the two recording sites (Carotid and 
femoral) is measured using a tape measure over the body area. The distance 
between the suprasternal notch and the carotid recording site (Proximal) is 
measured (Figure 22) as well as the distance between the suprasternal notch 
Methods                                                                     Chapter 5                                                                                                                                                            
 
114 
 
and the femoral recording site (Distal) (Figure 23). The difference between 
the proximal and distal distances is then calculated automatically by the 
device upon entering the former distances. The PWVcf is then calculated as 
PWVcf= Distance (m)/ tt (s). All PWVcf measurements acquired in our trial 
had an operator index range of 85-100%.  
 
 
Figure 17: The SphygmoCor device  
 
Methods                                                                     Chapter 5                                                                                                                                                            
 
115 
 
 
Figure 18: Recording the carotid pulse using Miller transducer 
 
Figure 19: Recording the femoral pulse using Miller transducer 
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Figure 20: Recording of the ECG 
 
 
 
 
                                 Figure 21: Proximal distance between suprasternal notch and carotid pulse detection point 
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Figure 22: Distal distance between suprasternal notch and femoral pulse detection point 
 
Furthermore, the coefficient of variation (CoV) for the SphygmoCor repeated 
measurements was 5%. In addition, limits of agreement (LoA) for the 
SphygmoCor repeated measurements ranged between -1.79 to 1.85 m/s with 
93% of the measurements falling within 2 SDs of the mean difference using 
Bland-Altman plot220 (Figure 24). 
 The same device was used for PWA. A hand-held high-fidelity tonometer 
(Miller tonometer, Houston, Texas, USA) was used for applanation tonometry 
of the right radial artery (Figure 25). The SphygmoCor device generated an 
average radial pulse wave contour after a 10 second recording period. This 
was then converted to a central pulse wave using a general transfer function 
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available within the SphygmoCor device221,222. AIx and ED % were then 
derived from PWA.  
 
 
 
 
Figure 23: Bland-Altman plot illustrating intra-rater reproducibility of the PWVcf 
measurements by the SphygmoCor device. The upper and lower dotted lines represent the 
level of agreement between repeated PWVcf measurements (mean difference +/- 2 SDs). 
The middle dotted line represents the mean of the difference between all repeated PWVcf 
measurements generated by the device     
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Figure 24: Applanation tonometry of the right radial artery using a high fidelity monometer 
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On the other hand, for the AIx measurements the LoA for the SphygmoCor 
repeated measurements ranged between -3 and 2% with 96% of the 
measurements falling within 2 SDs of the mean difference (Figure 26).  
 
 
 
 
Figure 25: Bland-Altman plot illustrating intra-rater reproducibility of the AIx 
measurements by the SphygmoCor device. For further detail, please see legend for figure 
24 
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The Vicorder Device Compared to SphygmoCor in the Assessment of Carotid 
Femoral Pulse Wave Velocity in Patients with PAD 
 
 
In order to establish which device has more reliability and validity in 
estimating PWVcf in patients with IC, an observational study was 
conducted220 comparing the Vicorder (Bristol, UK) which is a new device in 
the market for measuring PWVcf with the SphygmoCor which is considered 
by many as the gold standard for PWVcf measurement.   
 To this end, 30 patients with PAD (23 men, mean age 64.9 +/-7.5), who are 
some of the patients who took part in the original trial, underwent PWVcf 
measurement twice by a single investigator during one visit (Baseline) using 
the Vicorder and SphygmoCor according to manufacturers’ instructions. 
Intra-rater reproducibility for each device was assessed using intraclass 
correlation coefficients (ICC) and Bland-Altman method. The latter was also 
used to compare between the two devices. 
Measurements of PWVcf were highly reproducible using both devices 
(ICC=0.94 and 0.92, for the Vicorder and SphygmoCor, respectively). LoA 
using the Bland-Altman method were-1.07 to 1.09 m/s and -1.79 to 1.85 m/s 
for the Vicorder and SphygmoCor, respectively. Bland-Altman plots indicated 
that 90% of PWVcf measurements using the Vicorder and 93% of the 
measurements using the SphygmoCor fell within two standard deviations of 
the mean difference. Transit time differed significantly between the two 
devices (mean difference 30+/-9.2 ms, P<0.001) with the Vicorder recording 
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higher values. Nevertheless, the two devices recorded nearly similar PWVcf 
measurements (mean difference -0.69+/-1.6 m/s, P= 0.020) with 97% of 
PWVcf values falling within two standard deviations of the mean difference 
on Bland-Altman plot.  
To conclude, both devices generated highly reproducible PWVcf 
measurements in patients with PAD and were in good agreement when 
compared with each other. However, the discrepancy in transit time between 
the two devices lead to the Vicorder producing lower values of PWVcf at high 
values produced by SphygmoCor. This discrepancy in transit time generated 
by the Vicorder lead us to use the SphygmoCor for measuring PWVcf in the 
trial.    
 
 
Biomarkers of Inflammation, Ischaemia Reperfusion and 
Cardiovascular Prognosis 
 
 
 
The rationale behind measuring the following biomarkers has been discussed 
extensively in the introduction. Biomarkers of inflammation (CRP and 
Fibrinogen), biomarkers of ischaemia reperfusion (UACR at rest (r-UACR) and 
after exercise (t-UACR) and biomarker of cardiovascular prognosis 
(NTproBNP) were measured in the trial at baseline, 2,6 and 24 weeks follow-
up. The CRP assay had a sensitivity of 0.2 mg/l with a standard reference 
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range of 0.5-8mg/l and a CoV of <6%. To measure NTproBNP, blood samples 
were taken in EDTA Vacutainers and centrifuged at 4°C. The resultant plasma 
was analysed using an Elecsys 2010 analyser (Roche diagnostics). For the 
purpose of diagnosing heart failure, patients with NTproBNP plasma levels < 
300 pg/ml were unlikely to have heart failure and patients with levels > 500 
pg/ml were very likely to have heart failure223.   
 
Other Biomarkers 
Blood samples were obtained for a serum lipid profile including: Total 
cholesterol, triglyceride, LDL-C and HDL-C which was analysed using an 
enzymatic method. Furthermore, renal function was monitored closely 
throughout the trial by measuring urea, creatinine and estimated glomerular 
filtration rate (eGFR). All these measurements were obtained at baseline, 2,6 
and 24 weeks.      
 
 
Generic Quality of Life Assessment 
Short Form-36 
The generic SF-36 instrument (Figure 26-Appendix A) resulted from the 
Medical Outcomes Survey and the RAND health insurance experiment224-227. 
The aim was to produce a comprehensive, standardised, psychometrically 
sound practical instrument. This was to reduce the burden of prolonged 
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health surveys on both researchers and trial participants. The SF-36 has now 
become the most used health questionnaire in the world228.  It produces a 
comprehensive profile of eight domains covering the range of physical and 
psychological well-being: physical function, role limitation due to physical 
disability (Role – physical), bodily pain, general health perception, vitality, 
social function, role limitation due to emotional problems (Role – emotional) 
and mental health. Item scores for 36 questions are coded, summed and 
transformed on to a scale from 0 (Worst health) to 100 (Best health) in each 
domain.  
SF-36 has been extensively shown to be both valid and reliable in several 
health groups including patients with PAD229-236. Its global popularity has 
resulted in it being translated into 130 languages and norm based scores 
produced for a range of populations based upon population responses, 
making it a patient centred questionnaire. 
 
EuroQoL 
The EuroQol (EQ5D™; EuroQol Group, Rotterdam, The Netherlands) was 
developed by a multidisciplinary group of researchers from five European 
centres237 (Figure 27-Appendix A). It is an index scale, mapping three 
available responses to five questions onto a utility scale with 245 possible 
states. The UK weights were derived from TTO responses from 3000 adults 
from the general population238 with statistical modelling. The EQ5D has been 
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shown to be valid237,239,240 and is the recommended utility measure for cost 
utility analysis in the UK241. It is also a popular system world-wide with 150 
languages available. The EQ5D also includes a 100 point visual analogue 
scale, from “Worst imaginable health state” to the “Best imaginable health 
state”. 
 
Disease Specific Quality of Life Assessment 
 
King’s College VasculQoL 
 
The vascular QoL (VasculQol) questionnaire (Figure 28-Appendix A) was 
developed by a group of clinicians in the academic vascular department at 
King’s College Hospital242. The aim was to produce a disease specific QoL 
questionnaire for patients with chronic lower limb ischaemia and to design 
an evaluative instrument which is responsive to within subject variability that 
adds to clinical measures of outcome when comparing different treatment 
options for patients with lower limb ischaemia.  
The VascuQol questionnaire consists of 25 questions which cover five 
domains (Activities, symptoms, pain and emotional and social items) with 
each domain scored on a scale of 0 (Worst score) to 7 (Best score). 
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5.12 Quality Control and Quality Assurance 
 
 
Monitoring 
The study was monitored in accordance with the Hull and East Yorkshire 
Trust Research and Development (R&D) department’s standard operating 
procedures to ensure compliance with the UK clinical trials regulations. All 
trial related documents were made available upon request for monitoring by 
R&D monitors and for inspection by the Medicinal Health Regulatory Agency 
(MHRA). Monthly monitoring reports were completed and sent to R&D for 
regular trial up-dates. 
 
Ethical Review 
The final study protocol, including the final patient information and consent 
documents were given a favourable opinion by Ethics Committee prior to the 
study commencing. In addition Hull and East Yorkshire Trust R&D approval, 
Site Specific Assessment (SSA) approval and MHRA clinical trial authorisation 
was also acquired prior to commencing the study.  
Progress reports and notification of serious adverse events will be provided 
to the Ethics Committee according to local regulations and guidelines. 
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Ethical Conduct of the Study 
The study was conducted in accordance with The Medicines for Humans Use 
(Clinical trials) Regulations 2004 and Amendment Regulations 2006 and 
subsequent amendments; the International Conference for Harmonisation 
and Good Clinical Practice (ICH/GCP) guidelines; and the Research 
Governance Framework for Health and Social Care.  
All patients with IC were invited to enter the study if they fitted the 
inclusion/exclusion criteria. They were given a patient information sheet to 
read and a verbal discussion about the study by one of the study doctors. 
Patients who decided to enter the study were asked to sign a consent form. 
Patients were informed that they can leave the study at any time and that 
their future medical care will not be affected. 
All information collected about participants was collated using unique 
research numbers to ensure patients confidentiality.  No patients were 
named in any report or were identifiable. 
Anonymised data was stored on an NHS computer compliant with regulatory 
requirements in respect of patients’ confidentiality. Data will be kept for a 
maximum of 5 years. 
Data Handling and Record Keeping 
The chief investigator was responsible for data collection, recording and 
quality. Data was collected and retained in accordance with the Data 
Protection Act 1998. Study documents (paper and electronic) were retained 
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in a secure (kept locked when not in use) location during and after the trial 
has finished. All essential documents including source documents will be 
retained for a minimum period of 5 years after study completion (last patient, 
last visit). A label stating the date after which the documents can be 
destroyed was placed on the inside front cover of the case notes of trial 
participants.  
Indemnity  
This was an NHS –sponsored research study. If there was negligent harm 
during the clinical trial when the NHS body owes a duty of care to the person 
harmed, NHS indemnity covers NHS staff and medical academic staff with 
honorary contracts only when the trial has been approved by the R&D 
department. NHS indemnity does not offer no-fault compensation and is 
unable to agree in advance to pay compensation for non-negligent harm. 
 
5.13 Statistical Analysis 
All data was transcribed and recorded in a secured and dedicated database 
(Microsoft Excel®, Redmond, WA, USA). A Statistical Package for the Social 
Sciences Program (SPSS) version 18 for Windows (SPSS Inc. Chicago, IL) was 
used for statistical analysis.  
The statistical analysis was performed according to a standardised 
prospectively determined protocol. No assumptions were made at any time 
as to the direction of any relationships and no imputation of missing data was 
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attempted. Any key assumptions of the statistical techniques used were 
tested as appropriately. 
 
Continuous Data 
Continuous variables were expressed as mean +/- SD or adjusted mean 
changes (95% CI) or adjusted mean changes +/- standard error (SEM) for 
normally distributed data. If data was not normally distributed it was 
expressed as median (interquartile range (IQR)).    
Adjusted mean changes (95% CI) for outcome measures are presented using 
box graphs and tables. 
  
Analysis 
The distribution of continuous data was explored using histogram analysis 
prior to performing any statistical analysis. Any data which appeared to be 
normally distributed underwent further testing using the Kolmogorov- 
Smirnov statistic. This test assesses the normality of the distribution of 
values. For the purposes of this test, a non-significant result (P value > 0.050) 
indicates normality.   
Intragroup comparisons, featured the analysis of paired data (i.e. before and 
after in the same patient) and intergroup comparisons used unpaired data 
(i.e. from different patients). Hypothesis testing was performed comparing 
groups according to the data distribution and whether it was paired or 
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unpaired. The quoted “P-value” represents the probability of having 
observed the data if the null hypothesis were true243 (i.e. there is no actual 
differences between the data). “P-values” are quoted to three decimal places 
and a value of less than 0.050 was regarded as “significant” and led to 
rejection of the null hypothesis. 
Comparison between the groups at baseline was performed using the 
unpaired Student t-test (t test)244 for normally distributed data and Mann-
Whitney U (MWU)245 test for non-normally distributed data.  
Intragroup analysis of mean changes from baseline was tested using one-way 
repeated measures analysis of variance (ANOVA)246,247. Intergroup analysis 
was tested by means of one-way analysis of covariance (ANCOVA) model 
using baseline variables as the covariates in the model247. Therefore, adjusted 
mean changes +/- SEM or (95% CI) are displayed.  
Non-parametric baseline variables were log-transformed before being 
entered as covariates in the ANCOVA model247. Post-hoc comparisons were 
analysed using the Bonferroni correction. 
To examine the relationship between changes in walking distance from 
baseline at 24 weeks with corresponding changes in arterial stiffness indices, 
Pearson’s correlation coefficient (r) was used for univariate analysis.  
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Categorical Data 
Simple categorical data is presented as percentages (x/y) where x represents 
the number of cases in a category and y represents the total number of cases 
under consideration. 
 
Analysis 
The primary hypothesis test used in categorical analysis is Pearson’s Chi-
square test (χ2 test)248. If greater than 20% of expected frequencies are less 
than 5 or any are below 1, then Fisher’s exact test (FET)249 was used.  
 
Linear Regression Analysis 
Linear regression analysis was used to further examine covariates which were 
significant in the univariate analysis using Pearson’s correlation. Covariates 
which were statistically significant on univariate analysis were entered into 
the regression model with adjustment for HR and MAP.  
Linear regression was also performed using the enter method to determine 
whether ramipril effect on walking distance is related to its effect on systolic 
bBP and diastolic bBP.  
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6.1 Study Population:  
Flow of patients through the trial is presented in Figure 30. Overall, 166 
patients were assessed for eligibility over a period of 10 months from January 
2011; 38 patients were recruited and started on the run-in phase following 
which 5 patients withdrew and 33 patients were double-blind randomised to 
receive ramipril (n=14) or placebo (n=19), of whom, 29 patients (ramipril, 
n=12; placebo, n=17) completed all trial follow-ups.  
The most frequent reason for failing inclusion into the trial was being treated 
with ACE inhibitor or ARB (n=59) followed by declining to participate (n=27) 
in the trial and having an ABPI >0.9 (n=25).  
Baseline patients’ characteristics are summarised in table 8. There was no 
significant difference between the two groups in terms of demographics, 
cardiovascular risk factors, site of arterial disease or concomitant 
medications.  
Results                                                                                                                                              Chapter 6                                                                                    
 
133 
 
 
Assessed for eligibility 
n = 166 
Randomized 
n = 33 
Excluded n = 133 
   Did not meet inclusion criteria n = 101 
      On ACEI or ARB n = 59 
      ABPI > 0.9 n = 25 
      Recent angioplasty n = 9 
      Recent bypass n = 4 
      Rest pain or leg ulcers n = 4 
   Declined to participate n = 27 
   Other reasons n = 5 
 
 
 
Refused to participate n = 27 
Other reasons n = 
Allocated to ramipril n = 14 
Received ramipril n = 14 
Did not receive intervention n = 0 
Allocated to placebo n = 19 
Received placebo n = 19 
Did not receive intervention n = 0 
 
Lost to follow-up n = 2 
Withdrew owing  to cough n = 1 
       Withdrew owing to dizziness n=1 
Discontinued intervention n = 0 
  
Lost to follow-up n = 2  
Withdrew without giving reason n = 2 
Discontinued intervention n = 0  
Analysed n = 12 
Excluded from analysis n = 0 
 
Analysed n = 17 
Excluded from analysis n = 0 
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Figure 29: Consort diagram for the trial. ACEI: Angiotensin converting enzyme inhibitor, ARB: Angiotensin receptor blocker, ABPI: Ankle brachial pressure index 
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Table 8: Patients’ baseline characteristics. *Values are mean (SD).PAD: Peripheral arterial disease, †Fisher’s exact test except ‡unpaired t test 
 Ramipril 
(n = 14) 
Placebo 
(n = 19) 
 
P†  
Age (years)* 64.4(8.2) 64.7(7.7) 0.892‡ 
Sex ratio (M : F) 11 : 3 14 : 5 1.000 
Body mass index (kg/m2) 28.1(3.8) 28.3(4.2) 0.885‡ 
Cardiovascular risk factors  
   Smoking 
      Current smoker 7 9 1.000 
      Ex-smoker 7 6 0.472 
      Never smoker 0 4 0.119 
   Diabetes mellitus 4 7 0.738 
   Dyslipidaemia 12 18 0.561 
   Hypertension 7 13 0.472 
   Coronary artery disease 2 2 1.000 
Previous PAD treatment 
   Angioplasty 4 7 0.719 
   Peripheral bypass surgery 1 0 0.424 
Concomitant medications 
   Antiplatelet agents 14 17 0.496 
   Lipid-modifying agents 12 16 1.000 
   Beta-blockers 2 1 0.561 
   Calcium channel blockers 6 9 1.000 
   Diuretics 2 3 1.000 
Arterial stenosis site    
   Infrainguinal 12 15 1.000 
   Suprainguinal 0 2 0.496 
   Mixed 2 2 1.000 
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6.2 Primary Outcome Measure: Maximum Walking 
Distance 
 
Ramipril versus Placebo Effect on Maximum Walking 
Distance 
 
There was no significant difference between the ramipril and placebo groups 
at baseline in terms of MWD (median (IQR), 137 (110-213) versus 143 (72-
213) metres; P=0.760).  
Intragroup analysis showed that the mean change in MWD in the ramipril 
group increased significantly at 24 weeks compared to 2 weeks (P=0.006) and 
6 weeks (P=0.010 (P=0.226 for comparison between mean changes at 2 and 6 
weeks).  
In the placebo group, however, there was no significant increase in mean 
change in MWD at 24 weeks compared to 2 weeks (P=1.000) and 6 weeks 
(P=0.937) (P=0.134 for comparison at 2 and 6 weeks).  
Intergroup analysis showed that the adjusted mean change from baseline in 
MWD after 24 weeks of treatment with ramipril was 130.5 (95% CI 61.8 to 
199.2) metres  longer than with placebo (P = 0.001) (Figure 31a).  
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Figure 30a: Adjusted mean (SEM) changes in maximum walking distance in the ramipril 
and placebo groups at 2, 6 and 24 weeks. *P = 0.001 (1-way ANCOVA) 
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6.3 Secondary Outcome Measures: 
 
Ramipril versus Placebo Effect on Intermittent Claudication 
Distance 
 
There was no significant difference between the ramipril and placebo groups 
at baseline in terms of ICD (median (IQR) 81 (48–114) versus 94 (32–163) 
metres; P = 0.986).  
In the ramipril group, ICD increased significantly at 24 weeks compared with 
2 weeks (P = 0.020) and 6 weeks (P = 0.042) (P = 0.076 for comparison 
between mean changes at 2 and 6 weeks). 
 In the placebo group, there was no significant change at 24 weeks compared 
with 2 weeks (P = 0.693) and 6 weeks (P = 1.000) (P = 0.377 for comparison 
between changes at 2 and 6 weeks).  
The adjusted mean change in ICD with ramipril was 122 metres (95% CI 56 to 
188) metres  longer than with placebo after 24 weeks (P = 0.001) (Figure 
31b).  
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Figure 30b: Adjusted mean (SEM) changes in intermittent claudication distance in the 
ramipril and placebo groups at 2, 6 and 24 weeks. *P = 0.001 (1-way ANCOVA) 
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Ramipril versus Placebo Effect on Patient Reported Walking 
Distance 
 
The ramipril and placebo groups had significantly different baseline PRWD 
(median (IQR) 100 (87–263) and 229 (200–457) metres respectively; P = 
0.011).  
In the ramipril group, PRWD was non-significantly longer at 24 weeks 
compared with 2 weeks (P = 0.312) and 6 weeks (P = 1.000) (P = 0.585 for 
comparison between changes at 2 and 6 weeks). 
In the placebo group, there was no significant change in PRWD at 24 weeks 
compared with 2 weeks (P = 1.000) and 6 weeks (P = 0.816) (P = 1.000 for 
comparisons between mean changes at 2 and 6 weeks). Nonetheless, PRWD 
significantly improved after 24 weeks of treatment with ramipril, by 159 
metres (95% CI 66  to 313) metres  compared with placebo (P = 0.043) (Figure 
31c).  
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Figure 30c: Adjusted mean (SEM) changes in patient reported walking distance in the 
ramipril and placebo groups at 2, 6 and 24 weeks. *P = 0.043 (1-way ANCOVA) 
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Ramipril versus Placebo Effect on Ankle Brachial Pressure 
Index  
                      Ankle Brachial Pressure Index at Rest 
 
Baseline mean (SD) r-ABPI was comparable between the ramipril and placebo 
groups; 0.59(0.19) and 0.66(0.16) respectively, P = 0.250.  
Ramipril significantly increased r-ABPI by 0.03(0.08) at 24 weeks compared 
with 2 weeks (–0.04(0.09); P = 0.007) and non-significantly compared with 6 
weeks (–0.02(0.15); P = 0.590) (P = 0.560 for comparison between 2 and 6 
weeks).  
In the placebo group, there was no significant change in r-ABPI at 24 weeks 
(0.02(0.18)) compared with 2 weeks (0.002(0.11); P = 1.000) and 6 weeks 
(0.004(0.12); P = 1.000) (P = 1.000 for comparison between 2 and 6 weeks). 
There was no significant difference in adjusted mean changes of r-ABPI 
between the two groups at 2, 6 and 24 weeks (Figure 32).  In fact, r-ABPI 
improved slightly in both ramipril and placebo groups (0.02 (95% CI –0.08 to 
0.11) versus 0.03 (–0.05 to 0.10); P = 0.830). 
 
 
Ankle Brachial Pressure Index Post-exercise 
 
Baseline mean (SD) t-ABPI was comparable between the ramipril and placebo 
groups; 0.32(0.29) and 0.44(0.21) respectively, P = 0.188.  
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There was a non-significant increase in the ramipril group at 24 weeks 
(0.05(0.12)) compared with 2 weeks (0.03(0.07); P = 1.000) and 6 weeks 
(0.05(0.15); P = 1.000) (P = 1.000 for comparison between 2 and 6 weeks). 
There was no significant change in t-ABPI in the placebo group at 24 weeks 
(0.02(0.14) compared with 2 weeks (0.00(0.10; P = 1.000) and 6 weeks 
(0.04(0.10); P = 0.960) (P = 0.110 for comparisons between 2 and 6 weeks). 
There was no significant difference in adjusted mean (95% CI) changes in t-
ABPI between the ramipril and placebo groups at 2 weeks (0.03 (–0.03 to 
0.09) versus 0.005 (–0.04 to 0.05) respectively; P = 0.490), 6 weeks (0.05 (–
0.03 to 0.13) versus 0.05 (–0.02 to 0.11); P = 0.950) and 24 weeks (ramipril 
0.04 (–0.04 to 0.12) versus 0.02 (–0.04 to 0.09); P = 0.720).         
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Figure 31: Adjusted mean (SEM) changes in ankle brachial pressure index at rest in the 
ramipril and placebo groups at 2, 6 and 24 weeks 
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Ramipril versus Placebo Effect on Arterial Stiffness and 
Haemodynamic Measurements 
 
There was no significant difference in baseline PWVcf and indices of PWA 
between the two groups. However, there was a significant difference in 
baseline diastolic bBP between the groups (P = 0.021). Results of arterial 
stiffness and haemodynamic measurements throughout the trial are shown 
in Table 9.  
Ramipril decreased AIx after 24 weeks of  treatment compared with 2 weeks 
(P = 0.016); however, AIx non-significantly increased in the placebo group at 
24 weeks compared with 2 and 6 weeks (P = 0.012, P = 0.002 and P < 0.001 
for comparison between groups at 2, 6 and 24 weeks).  
Ramipril decreased AP at 24 weeks compared with 2 weeks (P < 0.001) and 6 
weeks (P < 0.001). Similarly, AP decreased in the placebo group at 24 weeks 
compared with 2 weeks (P < 0.001) and 6 weeks (P < 0.001) (P = 0.026 at 6 
weeks and P = 0.080 at 24 weeks for comparison between the groups).  
By 24 weeks, compared with placebo, ramipril significantly reduced PWVcf 
(adjusted mean  change –1.47 (95% CI –2.40 to –0.57) m/s; P = 0.002), 
systolic AoBP (P < 0.001) (P = 0.008 for comparison between the groups at 6 
weeks), diastolic AoBP (P = 0.020) (P = 0.005 for comparison between the 
groups at 2 weeks), aortic PP (P = 0.001), MAP (P < 0.001) (P = 0.021 for 
comparison between the groups at 6 weeks) and AIx@HR75 (P < 0.001)         
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(P = 0.004 and P = 0.001 for comparison between the groups at 2 and 6 
weeks respectively).  
There was a non-significant change in systolic bBP (P = 0.092), diastolic bBP (P 
= 0.183) (P = 0.022 and P = 0.005 at 2 and 6 weeks respectively) and brachial 
PP (P = 0.342).  
Ramipril significantly increased SEVR at 6 weeks (P = 0.011) and non-
significantly at 2 weeks (P = 0.281) and 24 weeks (P = 0.473) compared with 
placebo. No significant change in ED% was found between the groups at 2, 6 
or 24 weeks.  
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Table 9: Arterial stiffness indices at baseline, 2, 6 and 24 weeks in both groups. Values are mean (SEM). *P < 0.050, adjusted mean changes at 2, 6 and 24 weeks 
between groups (1-way ANCOVA); P < 0.050, within-group post hoc comparison between †weeks 2 and 24 and ‡weeks 6 and 24 (1-way repeated-measures 
ANOVA);  §P < 0.050, intergroup analysis at baseline (unpaired t test)
 Baseline Change at 2 weeks Change at 6 weeks Change at 24 weeks 
Placebo Ramipril Placebo Ramipril Placebo Ramipril Placebo Ramipril 
Brachial systolic blood pressure 
(mmHg) 
146(4) 139(5) –3(3) –7(4) –4(4) –17(4)* –2(3) –13(4) 
Brachial diastolic blood pressure 
(mmHg) 
82(1) 76(3)§ 0.5(2.0) –6(2)* –1(1) –7(2)* –0.2(1.0) –3(2) 
Brachial pulse pressure  (mmHg) 64(4) 63(5) –2(3) –3(3) –3(3) –10(4) –2(3) –6(3) 
Aortic systolic blood pressure 
(mmHg) 
139(6) 130(4) –3(3) –10(4) –1(4) –14(4)* 4(3) –16(3)* 
Aortic diastolic blood pressure 
(mmHg) 
83(2) 78(3) 2(2) –5(2)* –3(3) –9(3) –0.03(2.00) –6(2)* 
Aortic pulse pressure (mmHg) 55(6) 52(4) –4(3) –7(3) 3(5) –11(5) 5(2)† –10(3)* 
Mean arterial pressure (mmHg) 105(3) 99(3) –0.5(2.0) –7(2) –3(2) –10(3)* 2(2) –9(2)* 
Heart rate (beats/min) 70(2) 68(3) –0.2(1.0) 0.4(2) –0.3(1.0) –0.2(1.0) –2(2) 5(2)*‡ 
Augmentation pressure (mmHg) 19(2) 18(2) –1(1) –4(1) 2(2) –5(3)* 3(1)†‡ -7(2)†‡ 
Subendocardial viability ratio (%) 154(8) 144(7) 0.2(4.0) 8(5) –4(4) 15(5)* –1(4) 3(5) 
Ejection duration index (%) 35(1) 36(1) –0.03(1.00) –0.4(1.0) –0.1(1.0) –1(1) 0.3(1.0) 0.04(1.00) 
Augmentation index (%) 33(2) 34(3) 0.2(1.0) –4(1)* 2(1) –5(1)* 3(1) –8(1)*† 
Augmentation index adjusted to 
75 beats/min (%) 
31(1) 31(2) 0.6(1.0) –4(1)* 2(1) –5(1)* 2(1) –6(1)* 
Carotid femoral pulse wave 
velocity (m/s) 
10.7(0.6) 11.2(0.7) –0.2(0.3) –0.3(0.3) –0.9(0.3) –0.9(0.4) 0.6(0.3)‡ –0.9(0.3)* 
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Ramipril versus Placebo Effect on Biomarkers of 
Inflammation, Ischaemia Reperfusion and Cardiovascular 
Prognosis 
 
All laboratory measurements were comparable between the groups at 
baseline. Baseline and changes in laboratory measurements at 2, 6 and 24 
weeks between the groups are shown in Table 10.  
Intragroup analysis showed no significant change in the ramipril or placebo 
group in terms of lipid profile, eGFR, urea, creatinine, CRP, fibrinogen, 
NTproBNP, r-UACR and t-UACR, except for a significant change in total 
cholesterol in the ramipril group between 2 and 6 weeks (P = 0.020), and in 
LDL-C between the two groups at week 6 (P = 0.041).  
Nonetheless, after 24 weeks of treatment, there was a non-significant 
decrease in eGFR (P = 0.232) and NTproBNP (P = 0.452) in the ramipril group 
compared with placebo. Conversely, ramipril non-significantly increased 
creatinine (P = 0.070) and urea (P = 0.330) levels compared with placebo. 
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Table 10: Laboratory measurements at baseline, 2, 6 and 24 weeks in both groups. Values are mean (SEM) unless indicated otherwise; *values at baseline are median 
(interquartile range). HDL-C: High-density lipoprotein cholesterol, LDL-C: Low-density lipoprotein cholesterol, eGFR: Estimated glomerular filtration rate, CRP: C-reactive 
protein, NTproBNP: N-terminal pro b-type natriuretic peptide, r-UACR: Urine albumin creatinine ratio at rest, t-UACR: Urine albumin creatinine ratio after treadmill 
exercise test. †P < 0.050, adjusted mean change at 6 weeks between groups (1-way ANCOVA); ‡P < 0.050, within-group post hoc comparison between weeks 2 and 6 (1-
way repeated-measures ANOVA) 
 Baseline Change at 2 weeks Change at 6 weeks Change at 24 weeks 
Placebo Ramipril Placebo Ramipril Placebo Ramipril Placebo Ramipril 
Total cholesterol (mmol/l) 4.6(0.3) 4.4(0.2) 0.14(0.1) 0.04(0.10) 0.1(0.2) 0.3(0.2) –0.1(0.2) 0.3(0.2) 
LDL-C (mmol/l) 2.7(0.2) 2.2(0.2) –0.1(0.2) –0.1(0.2) –0.1(0.1) 0.6(0.2)† –0.2(0.2) 0.03(0.30) 
HDL-C (mmol/l) 1.2(0.1) 1.3(0.1) 0.02(0.04) 0.1(0.1) 0.02(0.04) 0(0.04) –0.02(0.04) 0.02(0.10) 
Triglycerides (mmol/l)* 1.4 (1.1–1.9) 1.7 (1.3–3.4) 0.3(0.2) 0.2(0.3) 0.4(0.2) –0.1(0.2) 0.6(0.3) 0.1(0.3) 
Total cholesterol/HDL-C 4.1(0.3) 3.9(0.4) 0.1(0.2) –0.3(0.1) –0.01(0.10) 0.3(0.2)‡ 0.02(0.20) 0.2(0.3) 
eGFR (ml/min/1.73 m2)* 81(73–90) 82 (70–90) 4(2) 1(3) –2(2) 0.01(2) –1(2) –5(3) 
Urea (mmol/l)* 4.4 (3.7–5.2) 4.7 (4.2–6.3) –0.2(0.3) –0.2(0.3) –0.2(0.2) –0.2(0.3) –0.5(0.3) 0.01(0.41) 
Creatinine (µmol/l) 81.6(3.3) 80(4) –2(2) –0.3(3.1) 3(2) 0.3(2) 0.8(3.0) 10(4) 
CRP (mg/l)* 3.6 (1.6–4.8) 2.7(1.2–4.8) –0.6(0.5) –0.5(0.6) –0.2(0.4) –0.7(0.5) 0.3(0.5) 0.2(0.5) 
Fibrinogen (g/l) 3.3(0.1) 3.5(0.2) –0.1(0.1) –0.1(1.0) –0.2(0.1) 0.01(0.1) –0.2(0.2) 0.1(0.2) 
NTproBNP (pg/ml )* 75 (48–212) 65 (27–161) 18(24) 4(28) –0.8(21.0) –6(25) 12(19) –11(23) 
r-UACR (mg/mmol)* 0.8 (0.4–1.5) 0.6 (0.2–2.4) –0.01(0.3) 0.1(0.3) 0.6(0.7) 0.9(0.8) –0.05(0.21) –0.1(0.3) 
t-UACR (mg/mmol)* 1.3 (0.7–2.2) 0.7 (0.2–3.2) –1(0.3) –1.0(0.3) –2(1) 0.04(1.00) –2(1) –2(1) 
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Ramipril versus Placebo Effect on Quality of Life 
 
Results from the three questionnaires (EQ-5DTM, SF-36® and VascuQol) are 
summarized in Table 11.  
Overall, patients had low scores in most domains at baseline, with the lowest 
scores in the domains physical function, role physical and bodily pain of the 
SF-36®, and pain and activities of VascuQol. There was no significant 
difference between the groups at baseline. In addition, there was no 
significant difference between the groups in any of the SF-36® and VascuQol 
domains after 24 weeks of treatment. VascuQol and EQ-5DTM total scores did 
not differ significantly between the groups after 24 weeks either.  
Patients in the ramipril group scored significantly lower in the mental health 
domain than patients who received placebo after 2 weeks (P = 0.040), but 
there was no significant difference at 6 and 24 weeks. Patients in the ramipril 
group had significantly lower scores in the social domain of VascuQol after 24 
weeks compared with week 2 (P = 0.040) and week 6 (P = 0.040). However, 
there was no such change in the placebo group. Notably, ramipril had a slight 
positive, but non-significant, effect on the domains physical function and 
bodily pain in the SF-36®, and pain and activities in the VascuQol; this was 
comparable to changes seen in the placebo group.    
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Table 11: Quality of life indices at baseline, 2, 6 and 24 weeks in both groups. Values are mean (SEM) unless indicated otherwise; *values at baseline are median 
(interquartile range). EQ-5D
TM
: EuroQol five-domain questionnaire, SF-36
®
: UK Short Form 36, version 1, VascuQol: King’s College Hospital’s vascular quality of life 
questionnaire.   †P < 0.050, adjusted mean change at 2 weeks between groups (1-way ANCOVA); P < 0.050, within-group post hoc comparison between ‡weeks 2 and 24 
and §weeks 6 and 24 (1-way repeated-measures ANOVA). 
 Baseline Change at 2 weeks Change at 6 weeks Change at 24 weeks 
Placebo Ramipril Placebo Ramipril Placebo Ramipril Placebo Ramipril 
EQ-5DTM score 0.73(0.02) 0.71(0.02) 0.02(0.02) 0.01(0.02) 0.03(0.02) 0.02(0.02) –0.01(0.02) 0.02(0.02) 
SF-36® domains  
   Physical function 53(5) 46(7) 3(3) 0.5(3.1) 2(3) 3(4) –0.9(5.1) 0.4(5.2) 
   Role physical 65(9) 46(10) –1(5) –9(6) –2(8) –1(9) –3(7) –11(8) 
   Bodily pain 57(5) 47(6) 7(4) 2(5) –3(4) 5(4) 1(4) 1(5) 
   General health 52(5) 48(7) 0.3(2.1) 3(3) 1(3) –1(4) 2(4) –2(4) 
   Vitality 50(5) 54(7) 2(3) –1(4) 2(3) 3(4) –2(4) –2(5) 
   Social function 74(6) 77(6) 0.6(4.1) –0.8(4.2) –2(4) –10(5) –7(5) –13(6) 
   Role emotional 79(8) 55(11) –1(6) 2(8) 3(7) 1(8) –7(8) –7(10) 
   Mental health 70(4) 78(6) 3(4) –9(4)† 4(4) –7(4) –3(3) –8(4) 
VascuQol domains  
   Pain 4.1(0.3) 4.0(0.4) 0.5(0.2) 0.6(0.2) 0.3(0.4) 0.5(0.4) 0.2(0.3) 0.5(0.4) 
   Social* 5.5 (3.5–7.0) 5.5 (4.0–6.0) –0.05(0.30) 0.4(0.3) –0.2(0.4) 0.4(0.5) –0.4(0.4) –0.2(0.5)‡§ 
   Emotional* 5.4 (3.9–6.2) 5.5 (4.1–6.1) 0.6(0.2) 0.5(0.2) 0.3(0.4) 0.5(0.5) 0.4(0.3) 0.2(0.4) 
   Symptoms* 5.5 (5.1–6.3) 5.4 (4.8–6.0) 0.08(0.20) –0.01(0.20) –0.04(0.30) 0.09(0.41) 0.01(0.20) –0.25(0.30) 
   Activities 4.0(0.3) 4.0(0.3) 0.5(0.2) 0.7(0.2) 0.4(0.3) 0.6(0.4) 0.3(0.3) 0.3(0.4) 
   Total score 5.0(0.3) 5.0(0.3) 0.4(0.2) 0.5(0.2) 0.3(0.3) 0.4(0.4) 0.2(0.3) 0.2(0.3) 
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6.4 Further Results 
 
 
Multivariable Regression Analysis 
 
 
Multivariable linear regression analysis which included change in MWD as a 
dependent variable and peripheral systolic and diastolic BP and class of drug 
(ramipril or placebo) as independent variables  showed that the ramipril-
induced change in MWD was not associated with its effect on systolic bBP 
(standardized β coefficient –0.03, P = 0.880) or diastolic bBP (standardized β 
coefficient –0.04, P = 0.871), but was independently associated with class of 
drug (ramipril or placebo; standardized β coefficient 0.60, P = 0.001) 
(adjusted R2 for model = 0.30, P = 0.008).  
 
To further test whether ramipril’s induced lowering of PWVcf and AIx are 
independent from potential confounding effects such as: HR and MAP for 
PWVcf and HR for AIx, we performed a multivariable regression analysis. 
Model 1 included PWVcf as the dependent variable and HR, MAP and class of 
drug (ramipril or placebo) as independent variables. Model 2 included AIx as 
dependent variable and HR and class of drug as independent variables. The 
results of the regression analysis for both models are summarized in table 11. 
These models clearly show that ramipril’s ability to reduce arterial stiffness is 
independent of potential confounding variables such as MAP and HR.  
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Correlation Analysis 
A correlation analysis was performed to investigate the relationship between 
walking distance and indices of arterial stiffness. Changes in MWD at 24 
weeks showed significant inverse correlation with indices of arterial stiffness 
(PWVcf, r=-0.43, P= 0.021; AIx, r= -0.50, P= 0.006; AIx@75 beats/min, r= -
0.50, P= 0.006; central PP, r= -0.38, P=0.039) (Figures 33-36).  
It is well known that indices of arterial stiffness are influenced by changes in 
HR and MAP . To adjust for these covariates, a multivariable regression 
analysis was conducted, where the relationship between changes in MWD at 
24 weeks and indices of arterial stiffness remained statistically significant 
(Table 12).   
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Figure 32: Relationship between changes in MWD and PWVcf at 24 weeks. The black line is 
the regression line 
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Figure 33: Relationship between changes in MWD and AIx at 24 weeks  
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Figure 34: Relationship between changes in MWD and AIx@75 beats/min at 24 weeks 
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Figure 35: Relationship between changes MWD and central PP at 24 weeks 
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Dependent Variable Independent Variables Β- coefficient P Value 
Model 1 :PWVcf MAP 0.14 0.458 
 HR -0.12 0.502 
 Group -0.44 0.018* 
Model 2: AIx HR -0.39 0.002* 
 Group -0.56 <0.001* 
 
Table 12: Multivariable regression analysis of ramipril induced lowering of arterial stiffness after adjustment for HR and MAP for PWVcf and HR for AIx 
with the group (ramipril or placebo) in both models. * P <0.050. PWVcf: Carotid-femoral pulse wave velocity, AIx: Augmentation index.  
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Dependent 
Variable 
Independent 
Variables 
Partial r 
value 
Standardised 
Coefficient (β) 
P value 
∆ MWD ∆ PWVcf  
∆ HR 
∆ MAP 
-0.33 
-0.08 
-0.15 
-0.32 
-0.09 
-0.15 
0.033* 
0.651 
0.437 
∆ MWD ∆ AIx 
∆ HR 
∆ MAP 
-0.40 
-0.03 
-0.34 
-0.35 
-0.03 
-0.32 
0.026* 
0.898 
0.099 
∆ MWD ∆ AIx@75 
∆ MAP 
-0.40 
-0.33 
-0.38 
-0.31 
0.037* 
0.118 
∆ MWD ∆ Central PP 
∆ HR 
∆ MAP 
-0.30 
 0.09 
-0.22 
-0.25 
 0.14 
-0.20 
0.044* 
0.649 
0.090 
 
 
Table 13: Multivariable regression analysis of the relationship between MWD and indices of arterial stiffness after adjustment for HR and MAP. * P 
<0.050. ∆: Change, PWVcf: Carotid-femoral pulse wave velocity, AIx: Augmentation index, AIx@75: Augmentation index adjusted to 75 beats/min, 
Central PP: Central pulse pressure. AIx@75 beats/min is only adjusted to MAP as it is already adjusted to HR.  
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6.5 Adverse Events 
 
 
Patients underwent clinical examination at each visit, including recording of 
vital signs, current medications and adverse events. Five of 38 patients 
enrolled in the run-in phase withdrew because of cough (4) and headache (1). 
Of 14 patients randomized to receive ramipril, four patients developed cough 
and one experienced dizziness. Consequently, two patients withdrew from 
the trial (1 owing to dizziness, 1 because of cough) (Figure 30).  
Of 19 patients randomized to placebo, two withdrew without giving a reason. 
One patient in the ramipril group developed hyperkalaemia by 6 weeks of 
follow-up, which was resolved without complications and the patients was 
able to complete the trial. Renal function was monitored closely throughout 
the trial and no deterioration was observed in any of the trial subjects.   
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7.1 Overview 
 
This trial was designed to compare the effect of ramipril, an ACE inhibitor, 
with placebo in patients with IC. Ramipril significantly improved MWD, ICD 
and PRWD, and decreased indices of arterial stiffness (PWVcf and AIx) 
compared with placebo. Ramipril had no significant effect on ABPI, 
biomarkers of inflammation and ischaemia–reperfusion, or QoL scores 
compared with placebo. Although NTproBNP, a surrogate marker of 
cardiovascular prognosis, was reduced in ramipril-treated patients, this effect 
was not statistically significant.  
This trial provides a significant contribution to the literature focused upon 
the clinical effectiveness of ramipril in patients with IC. It is the second 
randomised controlled trial on the subject in the world and the first in the 
United Kingdom and in Europe.  
Ramipril has been studied  previously for PAD; in a double-blind placebo-
controlled trial that was limited to non-diabetic patients with infrainguinal 
disease, Ahimastos and colleagues109 showed that ramipril improved MWT by 
243 per cent, PFWT by 164 per cent, r-ABPI by 0.07 and t-ABPI by 0.08 after 6 
months. In contrast, such major improvements were not observed in the 
present trial, which showed an improvement in MWD by 106 per cent and in 
ICD by 152 per cent, with non-significant improvements in r-ABPI and t-ABPI. 
The present trial included patients with diabetes and different levels of 
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arterial disease (Suprainguinal, infrainguinal and mixed), which makes this 
cohort more representative of the population with PAD. Nonetheless, at the 
time of writing this thesis, Ahimastos and colleagues published the results of 
the largest RCT on the subject250. The new trial by the Australian group 
assessed the effect of ramipril on walking distance and QoL in a cohort of 212 
patients with IC. Ramipril improved PFWT and MWT by 75 and 255 seconds, 
respectively, relative to placebo. Ramipril also improved the physical 
component of the SF-36 questionnaire by 8.2 (P=0.020) relative to placebo. 
The latter included patients with infra and suprainguinal disease and patients 
with diabetes which makes its results generalizable to PAD population.  
Our trial was in agreement with Ahimastos et al.250 in terms of the ability of 
ramipril to improve walking distance, however, it failed to show a positive 
effect on QoL or ABPI which contradicted the study by the Australian group.  
The effect of other ACE inhibitors (Cilazapril, captopril and perindopril) on 
walking distance or time has been studied in controlled trials106-108. These 
showed no significant improvement in walking distance, walking time or in 
ABPI. However, the duration of treatment with ACE inhibitors in these trials 
was relatively short (4–8 weeks) and two were crossover trials106,107 with only 
a small number of patients. The present trial suggests that a longer duration 
of treatment with an ACE inhibitor (6 months) improves efficacy.    
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From the clinical perspective, the most important finding of this trial was the 
improvement observed in ICD and MWD in the ramipril-treated group; 
however, this was not associated with improvements in QoL. In fact, ramipril 
had a slight non-significant effect on the domains physical function and pain. 
This trial may have been too small, as it was not powered to detect a 
difference in QoL between the two groups. 
 
7.2 Suggested Mechanisms of Action 
 
Improvement in Arterial Stiffness 
Arterial stiffness is associated with several pathological conditions including 
PAD180,251,252.  In general, there is a lack of evidence regarding ACE inhibitors 
effect on arterial stiffness in patients with PAD with one study180 in addition 
to our study assessing this effect. In Ahimastos et al. study180 and our study, 
improvement in arterial stiffness was studied as a potential factor in the 
improvement in walking ability observed in the two trials. Indeed, significant 
strong correlations were found between changes in MWD and changes in 
PWV in the ACE inhibitor-treated groups. This association remained 
significant after adjustment for HR and MAP. In this trial, ramipril decreased 
PWVcf and AIx after 24 weeks treatment period which is in agreement with 
the Australian trial180. The mean percentage change in PWVcf after 24 weeks 
of treatment was -9 +/-10% in the ramipril group compared to an increase of 
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5+/- 10% in the placebo group (P=0.001). Moreover, in a meta-analysis which 
included 469 patients with arterial stiffness, ACE inhibitor reduced pulse 
wave velocity by 1.69 m/s (P<0.00001) (See Chapter 4). Noteworthy, ramipril 
induced lowering of arterial stiffness in our trial was independent of its effect 
on potential confounding factors such as HR and MAP.   
The mechanism by which ACE inhibitors reduce arterial stiffness has been 
discussed in detail in the introduction. In brief, ACE inhibitors promote the 
elastogenic profile of the arterial wall by its inhibitory effect on the ECM and 
MMPs. In cell culture, ramiprilat decreased collagen deposition by more than 
50 per cent and increased elastin and fibrillin-1 deposition by 3-4 folds. It also 
decreased gene and protein expression of MMP-2 and MMP-3 in arterial 
wall21.  
The association between improvement in walking ability; observed in 
patients treated with ramipril; and reduction of arterial stiffness can be 
explained in relation to PP and calf blood flow. The latter is determined by BP 
in patients with PAD, although not the case in normal subjects253.  PP and 
mean pressure correlate positively with calf blood flow at rest. However, it is 
during exercise when calf blood flow becomes limited. Interestingly, baseline 
PP correlates negatively with walking distance253-255. Therefore, increased PP 
is associated with decreased walking ability in patients with IC. This can be 
attributed to decreased diastolic pressure and its inability to overcome the 
stiffened arteries found in patients with PAD to achieve sufficient blood flow 
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to the lower limbs. This mechanism is similar to the one that controls the 
relationship between arterial stiffness, PP and coronary ischaemic 
threshold256-258.   
There is substantial evidence that increased PP due to increased arterial 
stiffness is associated with impaired endothelial function, arterial wall 
hypertrophy and increased vascular resistance259-262. This is associated with 
further decrease of blood flow to the lower limbs in patients already having 
stenotic arteries and limited calf blood flow. In a cross sectional study of 2000 
patients from the Framingham cohort, increased PP and arterial stiffness 
were associated with decreased resting and hyperaemic microvascular blood 
flow independent of Framingham risk factors263.  Microvascular blood flow is 
largely dependent on structural changes in arterial wall which confirms the 
hypothesis that increased PP caused by increased arterial stiffness is 
associated with structural and functional changes in the arterial wall which 
decrease calf blood flow during exercise in patients with IC.  
Treatment with ramipril results in reduced aortic stiffness and PP which leads 
to an increase in diastolic pressure sufficient to overcome vascular resistance 
and improve blood flow to the lower limbs. Reduced arterial stiffness and PP 
will also result in improved microvascular structure and function which 
further improves calf blood flow in patients with IC.  
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Reduced arterial stiffness seem to be the most acceptable mechanism behind 
the improvements noted in walking ability in patients with IC treated with 
ramipril.   
 
Maintenance of Collateral Circulation and Angiogenesis 
Another potential mechanism of action is that ACE inhibitors increase blood 
flow to the legs by maintaining collateral circulation through their inhibitory 
effect on angiotensin II, a potent vasoconstrictor, and by reduction in the 
breakdown of bradykinin, causing vasodilatation. Roberts et al.106 have 
shown that captopril maintained collateral circulation to the lower limbs in 
patients with IC due to femoral artery stenosis which was explained by the 
vasodilatory effect of captopril.   
Angiogenesis264,265 is perhaps another suggested mechanism. Animal studies 
have shown that ACE inhibition with quinaprilat266 and imidapril 267 promoted 
angiogenesis in animal models of hind limb ischaemia. In the study by Fabre 
et al.266, quinaprilat, an ACE inhibitor with high tissue affinity promoted 
angiogenesis as potently as recombinant human vascular endothelial growth 
factor compared to captopril, an ACE inhibitor with low tissue affinity which 
did not promote angiogenesis. The mechanism of angiogenesis promoted by 
high tissue affinity ACE inhibitor most likely involves the increased availability 
of endothelial cell NO. This molecule is critical for the mitogenic effect of 
vascular endothelial growth factor on endothelial cells268.    
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Nonetheless, the improvement in walking distance observed in the ramipril 
cohort was not accompanied by significant improvements in ABPI; r-ABPI was 
almost unchanged after 24 weeks of treatment with ramipril and there was 
only a slight (non-significant) increase in t-ABPI after 24 weeks. This 
contradicts the theory that ramipril augmented collateral circulation in this 
cohort of patients through angiogenesis.  
 
Improvement in Endothelial Dysfunction 
Endothelial dysfunction is an early step in atherosclerosis that precedes 
morphological change to the arterial wall and has been linked to increased 
cardiovascular morbidity and mortality in patients with PAD269-272.  In addition 
to its prognostic value, endothelial dysfunction has been linked to the 
functional status in patients with PAD. In a cross sectional study of 111 
patients with PAD273, greater physical ability was associated with increased 
brachial flow mediated vasodilatation (FMD) (improved endothelial function). 
Furthermore, impaired endothelial function will result in a reduction in NO 
bioavailability in skeletal muscle microcirculation leading to decreased 
vasodilatation during exercise in patients with PAD which will further worsen 
IC274,275.   
In a meta-analysis276, ACE inhibitors improved endothelial function, measured 
by brachial FMD, by 1.26 per cent (P = 0.002) compared with placebo or no 
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treatment, and by 0.89 per cent (P = 0.009) compared with other 
antihypertensive agents in patients with several pathological conditions.  
The mechanisms by which ACE inhibitors improve endothelial dysfunction are 
based on their ability to inhibit angiotensin II production and to increase 
bradykinin. On one hand, angiotensin II, by binding to angiotensin II type 1 
receptor277, leads to vasoconstriction, endothelial cell migration, proliferation 
and hypertrophy 278-283, increased uptake and oxidation of LDL by endothelial 
cells and oxyradical production leading to endothelial dysfunction277. 
Moreover, angiotensin II stimulates the production of superoxide via 
increasing NADPH oxidase activity in the vascular smooth muscle284.  
ACE inhibitors, via inhibiting angiotensin II, will lead to inhibition of NAPDH 
oxidase and to a reduction in oxidative stress in the vascular tissue. This is 
important as increased oxidative stress in the vasculature has shown to 
predict the risk of future cardiovascular events 285.  
On the other hand, bradykinin, by binding to the bradykinin B2 receptor286, 
increases production and release of NO, prostacyclin 287,288and the 
endothelium-derived hyper- polarizing factor 289 which causes vasodilatation, 
inhibition of vascular smooth muscle cell proliferation and platelet 
adhesion290  and produces tissue plasminogen activator 291 which in turn 
restores the fibrinolytic balance. Therefore, inhibition of angiotensin II and 
increasing bradykinin production by inhibition of the angiotensin converting 
enzyme 292 will result in an improvement in endothelial function. 
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It is worth mentioning, however, that ACE inhibitors effect on endothelial 
dysfunction was never studied in the context of PAD.   
 
 
7.3 Can We Expect Similar Positive Effects From Other ACE 
Inhibitors?  
Most of the trials which showed beneficial effects of ACE inhibitors on 
walking distance used ramipril as the study treatment and for a long period 
of time (6 months). However, other studies which used other ACE inhibitors 
for a short period of time did not show similar benefits. This variability in ACE 
inhibitors effect on walking ability can be explained by different tissue 
affinities of ACE inhibitors.  Indeed, the degree of inhibition of tissue ACE 
produced by an ACE inhibitor is directly dependent on the binding affinity of 
the inhibitor and the concentration of the free inhibitor in the tissue which in 
turn is dependent on ACE inhibitors dose, bioavailability, blood half-life, 
tissue penetration and tissue retention. For instance, ramipril has a high 
tissue affinity and captopril a low tissue affinity. This can explain the positive 
effect on walking ability and ABPI noted in the trials which used ramipril for 
patients with IC. It is also worth mentioning that these trials used the 
maximum dose of ramipril for a relatively long treatment period compared to 
other trials which will further cause an increase in bioavailability and tissue 
retention.   
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In a recent updated systematic review and meta-analysis293 assessing the 
effect of ACE inhibitors on walking ability and ABPI which included data from 
our study294 and Ahimastos et al.250 new study in addition to the studies106-109 
which were included in the initial meta-analysis105 (See chapter 2), the three 
studies 109,250,294 which used ramipril as the study treatment showed a 
significant positive effect on walking ability and ABPI compared to studies 
which used other ACE inhibitors106-108 which showed worsening of walking 
ability and ABPI in patients with IC (Figures 37,38 and 39).  
 
 
 
Figure 36: Forest plot illustrating ACE inhibitors effect on changes in MWD compared with 
placebo. The x-axis is in metres. Small squares represent the differences in mean changes in 
MWD across individual studies between study groups (ACE inhibitor minus placebo). The 
95% CI for individual studies are represented by a horizontal line and by a diamond for 
pooled effect. SE: Standard error, IV: Inverse variance 
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Figure 37: Forest plot illustrating ACE inhibitors effect on changes in PFWD compared with 
placebo. The x-axis is in metres. For further detail see legend for figure 37. SE: standard 
error, IV: inverse variance 
 
 
 
Figure 38: Forest plot illustrating ACE inhibitors effect on changes in ABPI compared with 
placebo. For further detail see legend for figure 37. SE: Standard error, IV: Inverse variance 
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7.4 Are the Beneficial Effects of Ramipril on Walking 
Distance Generalizable to Races Other than the White 
Population? The Genetic Factor 
 
Although our trial294 and the two Australian studies109,250 have shown 
potential role for ramipril in the treatment of patients with IC, these trials 
were limited to the White population. It is well known that the ACE genotype 
plays a role in the variability of ACE activity. Individuals with the DD genotype 
display twice as high serum ACE concentrations as individuals with the II 
genotype295. Therefore, ACE inhibitors might work better in the I/D and II 
alleles than in the DD allele. This is true for the Caucasian and Asian 
populations but might be untrue in the African American population despite 
having the DD allele.  
Furthermore, Brewster et al.296 have shown that ACE inhibitors work better in 
the White population than in the Black population. Therefore, the favourable 
effects of ACE inhibitors noted in the White population with IC might not be 
observed in the Black population or other populations. 
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  7.5 Study Limitations 
 
Limitations of this study should be acknowledged. This study included a small 
number of patients due to high withdrawal rate because of cough. Patients 
included in our trial were offered smoking cessation advice but were not 
enrolled in a supervised exercise programme as this would have introduced 
intervention bias into the study. Furthermore, treadmill exercise test is an 
objective test which largely depends on patients’ motivation which might 
have introduced bias in the trial. Furthermore, the constant-load treadmill 
exercise test used in this trial does not permit an accurate assessment across 
the range of functional impairment in the broad population of PAD patients. 
For example, the incline used in our trial of 10% might have been extreme for 
patients with severe PAD. On the other hand, some patients with mild PAD 
might be able to walk for an extended period on a constant-protocol without 
being limited by claudication which precludes assessment of their maximal 
limitation. Thus, only a limited spectrum of patients with PAD can be 
assessed by the constant-load protocol. Although, the graded protocol better 
reflects the mechanism of the performance limitations in PAD, has the 
greatest reliability, and allows testing a wide range of functional disease 
severity in PAD, the constant-load protocol showed high intraclass correlation 
coefficient of 0.90 with walking time and both protocols are considered 
acceptable in measurement of walking distance in PAD297. Another challenge 
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or limitation which is worth mentioning is the improvement in walking 
distance overtime in patients randomised to placebo (Placebo response). The 
cause of this is likely multifactorial. Patients’ comfort and adjustment to 
walking on the treadmill and optimization of gait are potential factors. 
Another factor could be the change in walking efficiency. Nevertheless, the 
observed improvements in MWD, ICD and PRWD in the ramipril-treated 
group were significantly greater compared to the  slight insignificant 
improvement in the placebo group.  
The small number of patients enrolled into the study is a result of the 
difficulty we encountered during recruitment. The main reason behind this 
difficulty is that patients with IC would prefer to undergo percutaneous 
transluminal angioplasty than being managed conservatively. Furthermore, a 
large number of patients were already on ACE inhibitor or ARB which is 
considered exclusion criteria.  
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7.6 Conclusion 
In conclusion, this trial provides confirmatory level-1 evidence for using 
ramipril in the treatment of patients with PAD of the lower limbs. Ramipril 
improved walking distance and decreased arterial stiffness in patients with 
PAD. The improvement in walking distance is more than that achieved with 
other therapeutic agents for PAD such as pentoxifylline or cilostazol (80% 
improvement)298,299 but less than that of a supervised exercise programme 
(120% improvement)300. However, whether these favourable effects can be 
achieved in other ethnicities other than the White ethnicity remains to be 
seen. 
Future trials should focus on investigating the effect of ACE inhibitors on 
endothelial function in patients with PAD and its relationship to 
improvements in walking distance and possibly investigating the effect of 
ARBs on walking distance in this group of patients. However, as level-1 
evidence for using ACE inhibitors in patients with PAD is now available, trials 
investigating the effect of ARB on walking distance in PAD patients might be 
difficult to be ethically approved. Trials could also investigate the effect of 
ACE inhibitors in addition to a supervised exercise programme on walking in 
claudicants. 
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Appendix A: Quality of Life Questionnaires 
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Figure 26: Short Form-36 Questionnaire (UK version 2) 
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Figure 27: EuroQol Questionnaire 
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Figure 28: King’s College VasculQol Questionnaire 
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Appendix B: Patient Information Sheet 
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Appendix C: Patient Consent Form 
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